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ABSTRACT
CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS) is 20-40%. Our aim was to evaluate the 
effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. 
METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent 
randomized controlled trials (RCTs) on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline) 
(1966-2009), Controlled Trials of the Cochrane Collaboration (2009, Issue 2), Embase (Excerpta Medica) (1980-2009), Literatura Latino-Americana 
e do Caribe em Ciências da Saúde (Lilacs) (1982-2009). There was no language restriction. Randomized controlled trials, systematic reviews and 
meta-analyses evaluating atypical antipsychotics for treating RS were included. 
RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences 
between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence 
to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with 
favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. 
CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement 
in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which 
leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients. 
RESUMO 
CONTEXTO E OBJETIVO: De acordo com alguns estudos de coorte, a prevalência da esquizofrenia refratária (ER) está entre 20-40%. Nosso objetivo 
foi avaliar a efetividade e segurança de aripiprazol, paliperidona, quetiapina e risperidona no tratamento da esquizofrenia refratária.
MÉTODOS: Avaliação crítica das revisões Cochrane publicadas na Biblioteca Cochrane e complementação com referências de ensaios clínicos 
randomizados (ECRs) mais atualizados sobre ER. As seguintes bases de dados foram pesquisadas: Medline (Medical Literature Analysis and Retrieval 
System Online) (1966-2009), Ensaios Controlados da Colaboração Cochrane (2009, edição 2), Embase (Excerpta Database) (1980-2009), Lilacs 
(Literatura Latino-Americana e do Caribe em Ciências da Saúde) (1982-2009). Não houve restrição a idiomas. Ensaios clínicos randomizados, 
revisões sistemáticas e metanálises que avaliaram antipsicóticos atípicos no tratamento da esquizofrenia refratária foram incluídos.
RESULTADOS: Sete revisões sistemáticas Cochrane e 10 ECRs complementares foram incluídos nessa revisão. No geral os dados demonstram 
pequenas diferenças entre os antipsicóticos atípicos avaliados e os típicos na melhora dos sintomas da doença, apesar da melhor adesão ao 
tratamento com os atípicos. A risperidona foi avaliada especificamente em pacientes com esquizofrenia refratária em uma das revisões sistemáticas 
incluídas, a qual demonstrou desfechos favoráveis, porém não definitivos quando comparada a drogas também com eficácia comprovada como 
amisulprida, clozapina e olanzapina.
CONCLUSÕES: Os dados reforçam a dificuldade de tratar esses pacientes, com elevadas taxas de desistência do tratamento e padrões de melhora 
modestos nas avaliações de eficácia. Os antipsicóticos atípicos têm vantagens sobre os típicos principalmente pelo melhor perfil de segurança, o que 
leva a melhor adesão ao tratamento. A associação de antipsicóticos também pode ser uma opção em alguns pacientes refratários ao tratamento.
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INTRODUCTION
Refractory schizophrenia
Schizophrenia affects about 1% of the population and accounts for 
25% of psychiatric hospitalizations. Its course is variable, with about 
30% of cases presenting almost complete recovery; 30% in remission 
with incomplete and partial loss of function; and 30% with significant 
and persistent deterioration of professional, social, and emotional func-
tionality.
Approximately one-third of patients with schizophrenia do not re-
spond to first-generation antipsychotics.1 According to some cohort 
studies, the prevalence of refractory schizophrenia (RS) is between 20 
and 40% of schizophrenia patients.2 Some authors have reported high-
er rates; however, it has been questioned whether these findings might 
represent inappropriate treatment strategies regarding dose or duration 
of treatment.
It remains controversial in the literature regarding whether RS can 
be considered to be a more chronic and more severe subtype of schizo-
phrenia, characterized by refractory positive symptoms and poor social 
integration, or whether it must be understood as a distinct subtype of 
schizophrenia with well-defined neurochemical and anatomical charac-
teristics. Using magnetic resonance imaging, dopaminergic, serotoner-
gic and glutamatergic changes in the brain have been documented in 
patients with RS, compared with patients who responded well to treat-
ment.3
Some clinical features appear to be associated with RS. Patients with 
RS present greater severity of psychopathology (delusions and hallu-
cinations), have higher hospital admission recurrence rates, use more 
mental health resources, have poorer quality of life and pose a greater 
financial burden, both because they are removed from productive life 
and because they need help from others who, in turn, also see their 
work capacity reduced. Meltzer et al.,4 comparing patients with RS and 
non-RS, reported that patients with RS had an age at onset that was 
two years younger, and were more often men. Similarly, Henna et al.5 
observed that in terms of distribution between the genders, RS patients 
were predominantly male, had more hospitalizations and an onset at 
around 17 years of age, whereas those with non-refractory schizophrenia 
at an onset at around 20 years of age. Because RS patients are refracto-
ry to ordinary doses of typical antipsychotics, these patients are usually 
treated with doses that are much higher than the usual doses of medica-
tion, and with polypharmacy. 
Conceptual aspects of RS
There is a consensus in the literature regarding the core feature of 
RS: persistence of moderate to severe positive symptoms. Barnes et al.2 
reported that other dimensions of schizophrenia should be taken into 
account in diagnosing RS, such as negative symptoms and cognitive at-
tributes, as well as the inability to return to a higher level of premorbid 
functioning.
In 2002, the National Institute of Clinical Excellence6 defined RS, 
highlighting the characteristic of absence of satisfactory clinical im-
provement despite sequential use of recommended doses of at least two 
antipsychotics for 6-8 weeks (and one of the drugs had to belong to the 
second generation of antipsychotics), with assessments carried out using 
scales such as the Brief Psychiatric Rating Scale (BPRS) and the Clini-
cal Global Impression (CGI). Clinically, the multidimensional notion 
of RS may be useful, since it acknowledges the presence of persistent 
functional disability and psychosocial functioning disability despite ad-
equate treatment, thus causing inadequate definition in terms of a sim-
ple dichotomous (yes or no) determination. 
Some authors have tried to construct one-dimensional definitions 
based on overall reduction of symptoms or two-dimensional defini-
tions, taking into account the social adaptation and the reduction of 
symptoms. Barnes et al.2 and Brenner et al.7 defined RS as continuous 
resistance to treatment, and developed a scale based on psychopatholo-
gy and social adaptation. The operational criterion most widely used for 
defining RS in clinical studies is that of Kane et al,8 which was used in 
the study that introduced the therapeutic formulation clozapine into 
schizophrenia. The criterion of Kane et al.8 is three-dimensional: 1) His-
tory: a history of partial or total lack of response to previous treatment 
using two antipsychotics at adequate doses and for adequate periods; 2) 
Current (severity of symptoms): the patient must present a severe degree 
of psychopathology, as assessed by the BPRS and the CGI; and 3) Con-
firmatory: after treatment with one or more antipsychotic medications, 
the patient must show minimal improvement in symptoms (BPRS and 
CGI), compared with the levels of psychopathological conditions prior 
to treatment.
OBJECTIVES
The objective of this study was to undertake a systematic review to 
evaluate the effectiveness and safety of atypical antipsychotics (aripip-
razole, paliperidone, quetiapine and risperidone), compared with oth-
er antipsychotics or associations of interventions for treating refractory 
schizophrenia.
REVIEW METHODS
Criteria for study inclusion
Types of studies
Randomized controlled trials (RCTs) and systematic reviews (SRs) 
of randomized controlled trials were included. Quasi-randomized 
studies, defined as studies using inadequate allocation, such as date 
of birth, day of week, or assignment of subjects to alternative treat-
ments were included in the sensitivity analysis in order to assess ef-
fectiveness.
Studies published as abstracts were included when sufficient infor-
mation on methods and results were provided. For questions or incom-
plete data, the main authors were contacted and interviewed to obtain 
additional information or complement the existing data. 
Types of participants
Patients with refractory schizophrenia were included. Randomized 
clinical trials that evaluated patients with refractory and non-refractory 
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schizophrenia and did not distinguish between these groups in the anal-
ysis were not included. 
Types of interventions
•	 Intervention:	aripiprazole,	paliperidone,	quetiapine	or	risperidone,	
alone or combined with other interventions.
•	 Control	group:	typical	antipsychotics,	atypical	antipsychotics,	pla-
cebo, different doses of antipsychotics, discontinuation or intermit-
tent treatment.
Types of outcomes
Primary outcomes:
•	 Improved	overall	psychopathology:	scales	such	as	PANSS	(Positive	
and Negative Syndrome Scale), BPRS and CGI;
•	 Adherence	to	treatment:	time	until	discontinuation	of	medication,	
frequency of treatment discontinuation and reasons for discontinu-
ation.
•	 Improvement	of	specific	symptoms:	positive,	negative	or	cognitive.
Secondary outcomes: 
•	 Suicide.
•	 Specific	mortality,	i.e.	mortality	due	to	schizophrenia.
•	 Relapse:	appearance	of	positive	and	negative	symptoms.	
•	 Need	for	hospital	admission.
•	 Incidence	of	adverse	events.
•	 Quality	of	life.
•	 Cost	analysis.
Search strategy for studies 
Systematic reviews of the medications evaluated in this review were 
identified in the Cochrane Library. Since these reviews were not up to 
date, we conducted an additional search for randomized clinical trials 
that met the inclusion criteria. There was no language restriction, and 
studies were included whether published or not.
The date of the search was specific for each product, taking into 
consideration the date of the search in the systematic review assessed:
•	 Aripiprazole:	November	20079,10 
•	 Paliperidone:	December	200611 
•	 Quetiapine:	February	200312 
•	 Risperidone:	January	200213-15 
- Electronic databases
In association with a specific search phrase for randomized clinical 
trials, validated for each database, we used the following search strategy 
for this review: 
(schizophrenia	*	AND	(OR	resistant	OR	refractory	non-response	
*))	AND	((*	OR	abifity	aripiprazole)	OR	(quetiapine	seroquel	OR	*)	
OR	(risperidone	consult	*	OR)	OR	(paliperidone	INVEGA	*	OR)).	
The search strategy for clinical trials in Medline, via the PubMed in-
terface (1966-2009) was the following: 
(randomized	controlled	 trial	 [pt]	OR	controlled	 clinical	 trial	 [pt]	
OR	randomized	controlled	trials	[mh]	OR	random	allocation	[mh]	OR	
double-blind	method	[mh]	OR	single-blind	method	[mh]	OR	clinical	
trial	[pt]	OR	clinical	trials	[mh]	OR	(	“clinical	trial”	[tw])	OR	((singl	*	
[tw]	OR	double	*	[tw]	OR	Trebl	*	[tw]	OR	tripl	*	[tw])	AND	(mask	*	
[tw]	OR	blind	*	[tw]))	OR	(placebos	[mh]	OR	placebo	*	[tw]	OR	ran-
dom	 *	 [tw]	OR	 research	 design	 [mh:	 noexp]	OR	 comparative	 study	
[mh]	OR	evaluation	studies	[mh]	OR	follow-up	studies	[mh]	OR	pro-
spective	studies	[mh]	OR	control	*	[tw]	OR	prospectiv	*	[tw]	OR	vol-
unteer	*	[tw])	NOT	(animals	[mh]	NOT	human	[mh])).
The	 search	 strategy	 for	 clinical	 trials	 in	Embase	 via	Ovid	 (1980-
2009) was the following: 
Randomized controlled trial/ 2. Controlled study/ 3. Randomiza-
tion/	4.	Double	blind	procedure/	5.	Single	blind	procedure/	6.	Clinical	
trial/ 7. (clinical trial $ adj5). ti, ab, hw. 8. ((doubl $ or singl $ or tripl $ 
or $ Trebl) adj5 (blind $ or mask $)). ti, ab, hw. 9. Placebo / 10. Placebo 
$. Ti, ab, hw. 11. Random $. Ti, ab, hw. 12. Methodology.sh. 13. latin 
square.ti, ab, hw. 14. crossover.ti, ab, hw. 15. cross-over.ti, ab, hw. 16. 
Crossover	Procedure/	 17.	Drug	 comparison/	 18.	Comparative	 study/	
19. (comparative adj5 trial $). ti, ab, hw. 20. (control $ or prospectiv 
$	or	volunteer	$).	ti,	ab,	hw.	21.	exp	“Evaluation	and	Follow	Up”/	22.	
Prospective study/ 23. or/1-22 24. animal/no (human/and animal/) 25. 
23 not 24. 
The search strategy for clinical trials in the Lilacs (Literatura Lati-
no-Americana e do Caribe em Ciências da Saúde) (1982-2009) was the 
following:
((Pt	randomized	controlled	trial	OR	Pt	controlled	clinical	trial	OR	
Mh	randomized	controlled	trials	OR	Mh	random	allocation	OR	Mh	
double-blind	method	OR	Mh	 single-blind	method)	AND	NOT	(Ct	
animal	AND	NOT	(Ct	human	and	Ct	animal)).
- Websites visited
•	 http://www.controlledtrials.com	
•	 http://clinicaltrials.gov/ct/gui	
•	 http://www.CenterWatch.com/	
•	 http://www.fda.gov	
- List of references
References relating to trials and review articles that were identified 
were evaluated, in order to locate any additional studies not found in 
the databases. 
Study selection
Two reviewers independently assessed the titles and abstracts of all 
articles identified in the search, and evaluated the full texts of articles 
that described studies that might potentially be included in this review. 
Assessment of methodological quality
The methodological quality, defined as the degree of confidence that 
the design and reporting of the study were free from bias,16 was evalu-
ated by the authors, taking into account the results from the Cochrane 
systematic reviews included. For additional randomized clinical trials 
that were analyzed, the randomization process was the main method-
ological criterion evaluated. 
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Data analysis
The main meta-analyses in the systematic reviews were discussed 
and complemented with individual studies that evaluated patients with 
refractory schizophrenia. All the tests were performed using the inten-
tion to treat method, and all randomized patients were included in the 
analysis, regardless of their adherence or outcome. 
ARIPIPRAZOLE FOR TREATING REFRACTORY 
SCHIZOPHRENIA
Aripiprazole is an atypical antipsychotic for which the mechanism 
of action differs from other atypical antipsychotics (e.g. clozapine, olan-
zapine, quetiapine, risperidone and ziprasidone). Aripiprazole appears to 
exert	 its	effects,	 in	principle,	on	the	D2	receptor	partial	agonist,	which	
modulates dopaminergic activity in areas where dopamine activity may be 
increased or decreased, like the mesolimbic brain area.9 In addition to its 
partial	agonist	action	on	D2	receptors,	aripiprazole	is	also	a	partial	agonist	
of the 5-HT1A receptor.9
Two Cochrane systematic reviews have evaluated the use of aripip-
razole for treating schizophrenia. 
Cochrane review of aripiprazole for treating schizophrenia
The review by El-Sayeh and Morganti9 was a comprehensive re-
view that aimed to evaluate the effects of aripiprazole in treating general 
schizophrenia, compared with no intervention control. Fifteen studies 
were included, which evaluated 7,110 individuals. 
Compared with the placebo, aripiprazole significantly reduced the 
relapse rate over the short and midterm (n = 310; one RCT; relative risk, 
RR 0.66; confidence interval, CI 0.5 to 0.8; number needed to treat, 
NNT 5; CI 4-8) (Figure 1).17 
Aripiprazole promoted greater adherence to treatment, compared 
with the placebo (n = 2271; 8 RCTs; RR 0.72; CI 0.5 to 0.97; NNT 
26; CI 16-239).
However, no differences were found in relation to the overall state 
and the rate of dropout, in comparing aripiprazole with risperidone and 
olanzapine.
The rates of adverse events were also similar, with the exception 
of less elevated prolactin (n = 301, one RCT, RR 0.04 CI 0.02 to 0.1, 
NNT 2 CI 1 to 2.5) and lower QT prolongation medium (30 mg/day) 
(n	=	200;	one	RCT;	weighted	mean	difference,	WMD	-10.0;	CI	-16.99	
to -3.0), comparing aripiprazole with risperidone. 
Compared with typical antipsychotics, there were no benefits for 
aripiprazole in relation to the overall state, mental state, or quality of 
life. Both groups had similar rates of adverse events, with the exception 
of akathisia (n = 955; RR 0.31; CI 0.2 to 0.6; NNT 20; CI 17 to 32) 
and the need for antiparkinsonian medication (n = 1854; four RCTs; 
RR 0.45; CI 0.3 to 0.6; NNT 4; CI 3 to 5). These effects were less fre-
quent in patients taking aripiprazole (Figure 2).18-25 
The results from five new studies identified through updating this 
review did not significantly alter the main results and the initial find-
ings of this review. 
CONCLUSION
Aripiprazole is effective for treating schizophrenia, but not so dif-
ferent from typical and atypical antipsychotics with regard to treatment 
response, efficacy or tolerability. Compared with typical antipsychotics, 
aripiprazole presents a lower risk of akathisia, and compared with atypi-
cal antipsychotics, lower risk of increased prolactin levels and QTc inter-
val prolongation. 
Review: Aripiprazole for schizophrenia
Comparison: 1 ARIPIPRAZOLE versus PLACEBO
Outcome: 1 Overall state: 1. Relapse
Study or subgroup Aripiprazole
n/N
Placebo
n/N
Risk Ratio
M-H, Random, 95% CI
Weight Risk Ratio
M-H, Random, 95% CI
1 short term
Carson et al.17 50/155 85/155 38.5% 0.59 [0.45, 0.77]
Subtotal (95% CI) 155 155 38.5% 0.59 [0.45, 0.77]
Total events: 50 (Aripiprazole), 85 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.86 (P = 0.00011)
2 medium term
Carson et al.17 67/155 102/155 61.5% 0.66 [0.53, 0.81]
Subtotal (95% CI) 155 155 61.5% 0.66 [0.53, 0.81]
Total events: 67 (Aripiprazole), 102 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.86 (P = 0.00011)
Total (95% CI) 310 310 100.0% 0.63 [0.53, 0.74]
Total events: 117 (Aripiprazole), 187 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 = 0.0%
Test for overall effect: Z = 5.43 (P = 0.00001)
0.2 0.5 1.0 2.0 5.0
Favours aripiprazole Favours placebo
Figure 1. Efficacy of aripiprazole versus placebo, in relation to the outcomes of overall state and relapse, over the short and medium terms.
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Review: Aripiprazole for schizophrenia
Comparison: 2 ARIPIPRAZOLE versus TYPICAL ANTIPSYCHOTICS
Outcome: 5 Adverse effects: Clinically important specific adverse effects
Study or subgroup Aripiprazole
n/N
Typical
n/N
Risk Ratio
M-H, Random, 95% CI
Weight Risk Ratio
M-H, Random, 95% CI
1 anxiety
Kane et al.18 17/154 19/146 6.3% 0.85 [0.46, 1.57]
Subtotal (95% CI) 154 146 6.3% 0.85 [0.46, 1.57]
Total events: 17 (Aripiprazole), 19 (Typical)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
2 dyspepsia
Kane et al.18 17/154 9/146 5.7% 1.79 [0.82, 3.89]
Subtotal (95% CI) 154 146 5.7% 1.79 [0.82, 3.89]
Total events: 17 (Aripiprazole), 9 (Typical)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
3 extrapyramidal symptoms - akathisia
Daniel et al.19 9/235 9/60 5.4% 0.26 [0.11, 0.62]
Kane et al.18 6/154 13/146 5.1% 0.44 [0.17, 1.12]
Oren et al.20 1/175 7/185 2.3% 0.15 [0.02, 1.21]
Subtotal (95% CI) 564 391 12.8% 0.31 [0.17, 0.57]
Total events: 16 (Aripiprazole), 29 (Typical)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 2 (P = 0.56); I2 = 0.0%
Test for overall effect: Z = 3.77 (P = 0.00016)
4 extrapyramidal symptoms - general
Kane et al.18 5/154 9/146 4.7% 0.53 [0.18, 1.53]
Oren et al.20 3/175 24/185 4.3% 0.13 [0.04, 0.43]
Subtotal (95% CI) 329 331 9.0% 0.27 [0.07, 1.08]
Total events: 8 (Aripiprazole), 33 (Typical)
Heterogeneity: Tau2 = 0.67; Chi2 = 3.02, df = 1 (P = 0.08); I2 = 67%
Test for overall effect: Z = 1.85 (P = 0.064)
5 extrapyramidal symptoms - needing antiparkinson medication at least once
Carson et al.21,22 23/204 31/104 6.7% 0.38 [0.23, 0.61]
Csemansky et al.23 6/34 19/34 5.7% 0.32 [0.14, 0.69]
Daniel et al.24 37/121 28/63 7.0% 0.69 [0.47, 1.01]
Kujawa et al.25 198/861 247/433 7.5% 0.40 [0.35, 0.47]
Subtotal (95% CI) 1220 634 27.0% 0.45 [0.33, 0.60]
Total events: 264 (Aripiprazole), 325 (Typical)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.28, df = 3 (P = 0.06); I2 = 59%
Test for overall effect: Z = 5.23 (P < 0.00001)
6 headache
Daniel et al.19 32/235 5/60 5.3% 1.63 [0.67, 4.01]
Kane et al.18 9/154 13/146 5.6% 0.66 [0.29, 1.49]
Oren et al.20 13/175 16/185 6.0% 0.86 [0.43, 1.73]
Subtotal (95% CI) 564 391 16.9% 0.94 [0.57, 1.53]
Total events: 54 (Aripiprazole), 34 (Typical)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.26, df = 2 (P = 0.32); I2 = 12%
Test for overall effect: Z = 0.26 (P = 0.80)
7 insomnia
Kane et al.18 73/154 31/146 7.1% 2.23 [1.57, 3.18]
Oren et al.20 10/175 24/185 6.0% 0.44 [0.22, 0.89]
Subtotal (95% CI) 329 331 13.1% 1.02 [0.21, 5.08]
Total events: 83 (Aripiprazole), 55 (Typical)
Heterogeneity: Tau2 = 1.26; Chi2 = 16.46, df = 1 (P = 0.00005); I2 = 94%
Test for overall effect: Z = 0.03 (P = 0.98)
8 nausea
Daniel et al.19 17/235 4/60 4.8% 1.09 [0.38, 3.11]
Oren et al.20 10/175 4/185 4.5% 2.64 [0.84, 8.27]
Subtotal (95% CI) 410 245 9.2% 1.65 [0.69, 3.94]
Total events: 27 (Aripiprazole), 8 (Typical)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.27, df = 1 (P = 0.26); I2 = 21%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 3724 2615 100.0% 0.65 [0.45, 0.95]
Total events: 486 (Aripiprazole), 512 (Typical)
Heterogeneity: Tau2 = 0.48; Chi2 = 121.58, df = 17 (P < 0.00001); I2 = 86%
Test for overall effect: Z = 2.25 (P = 0.025)
0.1 0.2 0.5 1.0 2.0 5.0 10.0
Favours aripiprazole Favours antipsychotics typical
Figure 2. Aripiprazole versus typical antipsychotics, in relation to adverse effects.
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Cochrane review of aripiprazole compared with typical antipsychotics for 
treating schizophrenia
A second Cochrane review10 that specifically evaluated aripiprazole 
in comparison with typical antipsychotics for treating schizophrenia was 
updated. Nine randomized trials involving 3,122 individuals that com-
pared aripiprazole with typical antipsychotics were included. None of 
the studies reported the relapse rate. The dropout rate was high, as were 
the numbers of records with incomplete data. 
Patients using aripiprazole showed extrapyramidal symptoms less 
frequently than did those using typical antipsychotics (n = 968; three 
RCTs; RR 0.46; CI 0.3 to 0.9; NNT 13; CI 17 to 10) or, in particular, 
akathisia (n = 897; three RCTs, RR 0.39; CI 0.3 to 0.6; NNT 11; CI 9 
to 14) (Figure 3).18,20,21 
The occurrence of hyperprolactinemia was lower in patients taking 
aripiprazole, compared with those taking typical antipsychotics (n = 300; 
one RCT; RR 0.07; CI 0.03 to 0.2; NNT 2; CI 3 to 1). Patients taking 
aripiprazole had lower risks of sinus tachycardia (n = 289; one RCT; RR 
0.09; CI 0.01 to 0.8; NNT 22; CI 63 to 13) and blurred vision (n = 308; 
one RCT; RR 0.19; CI 0.1 to 0.7; NNT 14; CI 25 to 10), but increased 
risks of dizziness (n = 957. three RCTs; RR 1.88; CI 1.1 to 3.2; num-
ber needed to harm, NNH 20; CI 33 to 14) and nausea (n = 957; three 
RCTs; RR 3.03; CI 1.5 to 6.1; NNH 17; CI 25 to 13. The dropout rates 
were high in both groups, although significantly more participants in the 
aripiprazole group completed the study, over the long term (n = 1294; 
one RCT; RR 0.81; CI 0.8 to 0.9; NNT 8; CI 5 to 14).
Review conclusion
Aripiprazole differs little from typical antipsychotics with regard to 
efficacy. However, it has significant advantages in terms of tolerability. 
Further studies are needed in order to replicate and validate these results 
and determine the effectiveness of aripiprazole in clinical practice.
Studies of refractory schizophrenia
From the updated search, two RCTs were selected that were not in-
cluded in the systematic reviews mentioned above, which evaluated the 
effectiveness of aripiprazole for treating refractory schizophrenia.
Chang et al.26 conducted a randomized, double-blind study evaluat-
ing the efficacy and safety of aripiprazole associated with clozapine among 
patients with refractory schizophrenia. Patients diagnosed with schizo-
phrenia	according	to	the	DSM-IV	(Diagnostic	and	Statistical	Manual	of	
Mental	Disorders)	and	with	a	history	of	treatment	failure	or	partial	re-
sponse to long-term use of clozapine were recruited. Sixty-two patients 
evaluated using the Brief Psychiatric Rating Scale (BPRS) (scoring at least 
35) and SANS (Scale for the Assessment of Negative Symptoms) were 
randomly assigned to one of two groups: aripiprazole associated with clo-
zapine (5-30 mg/day) or placebo for eight weeks. The primary outcome 
assessed was a change in the total BPRS score at baseline and no signifi-
cant difference in this outcome between the two groups. In secondary 
analysis, the improvement was significantly greater with aripiprazole as-
sociated with clozapine than with a placebo, in relation to negative symp-
toms assessed using the negative symptom subscales of the BPRS and 
SANS scales (total score). Prolactin levels and triglycerides were signifi-
cantly lower in the aripiprazole group than in the placebo group. There 
was no significant difference between the two groups in relation to adverse 
effects, including extrapyramidal symptoms and hyperglycemia. The au-
thors concluded that although aripiprazole associated with clozapine did 
not lead to significant improvement in all symptoms of schizophrenia, a 
favorable change in areas relating to negative symptoms was observed.
Kane et al.27 conducted a randomized, multicenter, double-blind tri-
al comparing the efficacy and safety of aripiprazole and perphenazine in 
patients with refractory schizophrenia. They included patients diagnosed 
according	to	the	DSM-IV	and	with	a	history	of	resistance	to	treatment.	
Patients received four to six weeks of open treatment with olanzapine or 
risperidone	to	confirm	treatment	resistance.	Only	patients	who	completed	
this open period without response (< 20% improvement in subscales relating 
to the positive and negative syndrome scale (PANSS) total score or Clinical 
Global Impression Score ≥ 4) were included in the six weeks of double-blind 
treatment. In all, 300 patients with confirmed resistance to treatment were 
randomized into two groups: aripiprazole (15-30 mg/day) or perphenazine 
(8-64 mg/day). The primary outcome was measured as changes in the 
PANSS scores. Both groups (aripiprazole and perphenazine) showed sig-
nificant clinical improvement according to PANSS total scores. After six 
weeks, 27% of the patients treated with aripiprazole and 25% of the pa-
tients treated with perphenazine responded to treatment (≥ 30% reduc-
tion in PANSS total score or a Clinical Global score of 1 or 2). Patients 
treated with perphenazine reported higher incidence of extrapyramidal 
Figure 3. Aripiprazole versus typical antipsychotics, in relation to extrapyramidal symptoms
Review: Aripiprazole versus typical antipsychotic drugs for schizophrenia
Comparison: 1 Aripiprazole versus typical antipsychotic drugs (short term </=12 weeks)
Outcome: 5 Adverse effects: extra-pyramidal symptoms
Study or subgroup Aripiprazole 
n/N
Typical 
n/N
Risk Ratio 
M-H, Fixed , 95% CI
Weight Risk Ratio 
M-H,Fixed, 95% CI
1 EPS-related adverse event
Carson et al.21 38/204 37/104 45.5% 0.52 [0.36, 0.77]
Kane et al.18 21/154 28/146 38.6% 0.71 [0.42, 1.19]
Oren et al.20 3/175 23/185 15.8% 0.14 [0.04, 0.45]
Subtotal (95% CI) 533 435 100.0% 0.46 [0,25, 0.87]
Total events: 62 (Aripiprazole), 88 (Typicals)
Heterogeneity: Tau2 = 0.20, Chi2 = 6.47, df = 2 (P = 0.04); I2 = 69%
Test for overall effect: Z = 2.40 (P = 0.016)
0.1 0.2 0.5 1.0 2.0 5.0 10.0
Favours aripiprazole Favours antipsychotics typical
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symptoms and higher prolactin levels than in patients treated with arip-
iprazole (57.7% versus 4.4%, P < 0.001). The improvement in quality of 
life was considered clinically relevant according to the results (≥ 20% im-
provement in score on the quality-of-life scale). This was found in 36% 
of patients treated with aripiprazole and 21% of those treated with per-
phenazine (P = 0.052). The authors concluded that at the doses described 
in this study, aripiprazole and perphenazine may improve the symptoms 
of refractory schizophrenia in patients who have not responded to olan-
zapine or risperidone.
PALIPERIDONE FOR TREATING REFRACTORY 
SCHIZOPHRENIA
Paliperidone is the active metabolite of risperidone, and is used as 
an atypical antipsychotic oral medication or as an injectable depot for 
monthly usage. 
Cochrane Review on paliperidone for treating schizophrenia 
In the review by Nussbaum and Stroup,11 five RCTs comparing oral 
paliperidone with placebo (n = 1647) and three RCTs comparing with 
olanzapine, quetiapine, risperidone  (n = 1332) were included. No RCTs 
studying injections of paliperidone with prolonged action were identified.
Compared with placebo, the patients receiving paliperidone had a 
lower dropout rate in the study (n = 1647; five RCTs; RR 0.68; CI 0.61 
to 0.76; NNT 7; CI 6 to 9) (Figure 4).27-31
The patients taking paliperidone had higher rates of improvement 
in general condition and disease symptoms, compared with placebo 
(n = 1420; four RCTs; RR 0.69; CI 0.63 to 0.75; NNT 5; CI 4 to 6) 
(Figure 5).27,28,30-31
The use of paliperidone resulted in lower recurrence of psychosis (n 
= 1638; five RCTs; RR 0.45; CI 0.31 to 0.66; NNT 16; CI 13 to 26) 
(Figure 6).27-31
With	 regard	 to	 adverse	 events,	 in	 comparison	with	placebo,	pali-
peridone resulted in: 
•	 higher	incidence	of	tachycardia	(n	=	1638;	five	RCTs;	RR	1.88;	CI	
1.3 to 2.86; NNH 21; CI 11 to 90); 
•	 significantly	higher	elevation	of	prolactin,	for	both	men	(n	=	413,	
4	RCTs,	WMD	27.68;	CI	23.66	to	31.69)	and	women	(n	=	252,	4	
RCTs,	WMD	87.39;	CI	74.27	to	100.51);	
•	 higher	rate	of	extrapyramidal	disorders	(n	=	1638;	five	RCTs;	RR	
2.21; CI 1.3 to 3.9; NNH 28; CI 12 to 129); 
•	 greater	weight	gain	(n	=	769,	4	RCTs,	WMD	1.07;	CI	0.65	to	1.49;	
I2 index 78%) in the meta-analysis of three RCTs comparing paliper-
idone with olanzapine. The loss rate during the studies was similar 
in both groups of patients (around 40% over six weeks of study). 
In assessing the improvement of symptoms over the six-week period, 
there was no significant difference favoring olanzapine in the PANSS as-
sessment	(n	=	715;	DMP	2.44;	CI	-0.52	to	5.35)	(Figure 7).27,28,30
Regarding the profile of adverse events, the main differences be-
tween the use of paliperidone and olanzapine occurred in relation to 
weight gain and movement disorders. The group taking paliperidone 
had	lower	weight	gain	(n	=	660;	three	RCTs;	DMP	-0.88;	CI	-1.38	to	
-0.37).
Patients taking olanzapine had a lower rate of movement disorders 
(Figure 8):27,28,30
•	 extrapyramidal	disorders	(n	=	1327;	three	RCTs;	RR	2.99;	CI	1.4	to	
6.2);
•	 hyperkinesis	(n	=	1327;	three	RCTs;	RR	3.14;	CI	1.5	to	6.4);
•	 stiffness	(n	=	1327;	two	RCTs;	RR	9.28;	CI	1.3	to	68.5).
Conclusions from review
In short-term studies, oral paliperidone is more effective than pla-
cebo. Its safety profile is similar to that of risperidone, with movement 
disorders, weight gain and tachycardia more common with paliperidone 
than with placebo. In addition, paliperidone is associated with signifi-
cant increases in serum prolactin, which can cause sexual dysfunction, 
although this outcome was not assessed in this review because of lim-
ited data from the individual studies. At a dose of 3 mg/day, oral pali-
peridone appears to have efficacy similar to oral olanzapine 10 mg/day. 
There is a need for studies comparing paliperidone with risperidone be-
cause of the great similarity of these drugs.
Studies on refractory schizophrenia
The search for RCTs did not identify any studies on paliperidone 
used for patients with refractory schizophrenia. However, two RCTs 
other than those included in the Cochrane review are presented below. 
Turkoz et al.32 evaluated the effect of paliperidone on negative symp-
toms of schizophrenia, through a meta-analysis on three RCTs consist-
ing of placebo-controlled trials of six weeks duration (937 patients with 
paliperidone and 337 on placebo). In these studies, it was determined 
that 33% of the improvement in negative symptoms was due to the di-
rect action of paliperidone, and the remainder was due to improvement 
in positive symptoms (51%), anxiety and depressive symptoms (18%) 
and movement disorders (2%). The study concluded that paliperidone 
produced effective action on negative schizophrenia symptoms. 
Canuso et al.33 published an RCT comparing paliperidone with que-
tiapine and placebo among 399 patients hospitalized due to relapse of 
schizophrenia.	Over	the	first	two	weeks	of	the	study,	the	patients	remained	
on monotherapy, and over the subsequent four weeks, the psychiatrists 
could combine another psychotropic drug, including an antipsychotic. 
At the end of the six weeks of the study, the patients in the paliperidone 
group had a significantly greater improvement in measurements such as 
PANSS (P = 0.023) than did patients using quetiapine, considering that 
the pattern of associations with other drugs was similar in both groups. 
Throughout the study, paliperidone was superior to quetiapine and place-
bo in improving negative symptoms (PANSS subscale, P < 0.005).
QUETIAPINE IN TREATMENT-REFRACTORY 
SCHIZOPHRENIA
Cochrane review on quetiapine for treating schizophrenia
Twelve RCTs were included in the review by Srisurapanont et al.,12 
comprising a total of 3,443 individuals with schizophrenia. 
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Figure 4. Paliperidone versus placebo, in relation to dropout rate in the study. 
Review: Paliperidone for the treatment of adults with schizophrenia
Comparison: 1 PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus PLACEBO (all short term)
Outcome: 1 Leaving the study early
Study or subgroup Paliperidone
n/N
Placebo
n/N
Risk Ratio
M-H, Fixed, 95% CI
Weight Risk Ratio
M-H, Fixed, 95% CI
1 any reason
Davidson et al.28 137/367 76/123 33.6% 0.60 [0.50, 0.73]
Kane et al.27 108/375 69/127 30.4% 0.53 [0.42, 0.66]
Kramer et al.29 20/105 8/102 2.4% 2.43 [1.12, 5.26]
Marder et al.30 119/224 73/110 28.9% 0.80 [0.67, 0.96]
Tzimos et al.31 12/76 12/38 4.7% 0.50 [0.25, 1.01]
Subtotal (95% CI) 1147 500 100.0% 0.68 [0.61, 0.76]
Total events: 396 (Paliperidone), 238 (Placebo)
Heterogeneity: Chi2 = 20.37, df = 4 (P = 0.00042); I2 = 80%
Test for overall effect: Z = 6.79 (P < 0.00001)
2 adverse event
Davidson et al.28 13/367 5/123 22.9% 0.87 [0.32, 2.39]
Kane et al.27 20/375 9/127 41.2% 0.75 [0.35, 1.61]
Kramer et al.29 3/105 1/102 3.1% 2.91 [0.31, 27.56]
Marder et al.30 14/224 5/110 20.5% 1.38 [0.51, 3.72]
Tzimos et al.31 5/76 3/38 12.5% 0.83 [0.21, 3.30]
Subtotal (95% CI) 1147 500 100.0% 0.98 [0.62, 1.57]
Total events: 55 (Paliperidone), 23 (Placebo)
Heterogeneity: Chi2 = 1.92, df = 4 (P = 0.75); I2 = 0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
3 lack of efficacy
Davidson et al.28 68/367 54/123 37.2% 0.42 [0.31, 0.57]
Kane et al.27 52/375 51/127 35.0% 0.35 [0.25, 0.48]
Marder et al.30 42/224 39/110 24.1% 0.53 [0.36, 0.77]
Tzimos et al.31 3/76 6/38 3.7% 0.25 [0.07, 0.95]
Subtotal (95% CI) 1042 398 100.0% 0.41 [0.34, 0.50]
Total events: 165 (Paliperidone), 150 (Placebo)
Heterogeneity: Chi2 = 3.40, df = 3 (P = 0.33); I2 = 12%
Test for overall effect: Z = 9.24 (P < 0.00001)
4 loss to follow up
Davidson et al.28 3/367 0/123 6.2% 2.36 [0.12, 45.34]
Kane et al.27 3/375 2/127 24.6% 0.51 [0.09, 3.01]
Kramer et al.29 2/105 3/102 25.1% 0.65 [0.11, 3.80]
Marder et al.30 18/224 4/110 44.2% 2.21 [0.77, 6.37]
Subtotal (95% CI) 1071 462 100.0% 1.41 [0.67, 2.97]
Total events: 26 (Paliperidone), 9 (Placebo)
Heterogeneity: Chi2 = 2.82, df = 3 (P = 0.42); I2 = 0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
5 non compliance
Davidson et al.28 3/367 0/123 12.6% 2.36 [0.12, 45.34]
Kane et al.27 0/375 0/127 0.0% Not estimable
Kramer et al.29 1/105 0/102 8.5% 2.92 [0.12, 70.74]
Marder et al.30 3/224 3/110 67.7% 0.49 [0.10, 2.39]
Tzimos et al.31 1/76 0/38 11.2% 1.52 [0.06, 36.44]
Subtotal (95% CI) 1147 500 100.0% 1.05 [0.34, 3.19]
Total events: 8 (Paliperidone), 3 (Placebo)
Heterogeneity: Chi2 = 1.62, df = 3 (P = 0.66); I2 = 0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
6 unspecified participant reason
Davidson et al.28 43/367 13/123 36.6% 1.11 [0.62, 1.99]
Kane et al.27 28/375 7/127 19.6% 1.35 [0.61, 3.03]
Kramer et al.29 12/105 0/102 1.0% 24.29 [1.46, 404.98]
Marder et al.30 40/224 17/110 42.8% 1.16 [0.69, 1.94]
Subtotal (95% CI) 1071 462 100.0% 1.40 [1.00, 1.96]
Total events: 123 (Paliperidone), 37 (Placebo)
Heterogeneity: Chi2 = 5.08, df = 3 (P = 0.17); I2 = 41%
Test for overall effect: Z = 1.94 (P = 0.052)
7 unspecified reason
Davidson et al.28 7/367 4/123 33.6% 0.59 [0.17, 1.97]
Kane et al.27 5/375 0/127 4.2% 3.74 [0.21, 67.25]
Kramer et al.29 2/105 3/102 17.1% 0.65 [0.11, 3.80]
Marder et al.30 2/224 5/110 37.6% 0.20 [0.04, 1.00]
Tzimos et al.31 1/76 1/38 7.5% 0.50 [0.03, 7.78]
Subtotal (95% CI) 1147 500 100.0% 0.58 [0.28, 1.19]
Total events: 17 (Paliperidone), 13 (Placebo)
Heterogeneity: Chi2 = 3.33, df = 4 (P = 0.50); I2 = 0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
3 lack of efficacy
Davidson et al.28 43/367 13/123 93.6% 1.11 [0.62, 1.99]
Tzimos et al.31 2/76 1/38 6.4% 1.00 [0.09, 10.68]
Subtotal (95% CI) 443 161 100.0% 1.10 [0.62, 1.95]
Total events: 45 (Paliperidone), 14 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 = 0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
0.2 0.5 1 2 5
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In four comparative studies with placebo (n = 716), there was a high 
dropout rate during the study: 53% loss with quetiapine and 61% for 
the placebo (RR 0.84; CI 0.7 to 0.9; NNT 11; CI 7 to 55), which lim-
ited the interpretation of other outcomes (Figure 9).34-55
In three studies (n = 1066) that compared higher doses of quetia-
pine (≥ 250 mg/day) with lower doses (< 250 mg/day), there were also 
high dropout rates in both groups. The group with higher doses had a 
49% dropout rate, compared with 58% for lower doses (RR 0.84; CI 
0.8 to 0.9; NNT 11; CI 7 to 29). It should be noted that there were two 
deaths in the group receiving the higher dose in one RCT (n = 618; RR 
0.1; CI 0.0 to 2.1) (Figure 10).34-51,56-62
There was a non-significant difference favoring the group receiving 
the higher doses of quetiapine, with regard to improving mental status 
(n = 1066; three RCTs; RR 0.93; CI 0.82 to 1.05) (Figure 11).34-51,56-62
In six studies comparing quetiapine with typical antipsychotics 
(n = 1924), the short-term dropout rate was around 36% in both groups 
(RR 0.87; CI 0.8 to 1.0). The outcomes related to symptomatic im-
provement in general, with no significant differences between quetiap-
ine and typical antipsychotics:
•	 In	assessing	the	overall	improvement	over	the	short	and	midterm,	the	
results favored typical antipsychotics, despite the borderline statisti-
cal	result	(n	=	762;	DMP	0.2;	CI	0.0	to	0.4)	(Figure 12).37-51,63-69
•	 There	 was	 no	 difference	 in	 the	 improvement	 in	 mental	 status	
(n = 1247; RR 0.97; CI 0.9 to 1.1) (Figure 13).37-51,65-80
•	 There	was	no	difference	in	the	improvement	in	negative	symptoms	
(n	=	305;	one	RCT;	DMP	0.94;	CI	-0.2	to	2.0)	(Figure 14).37-51,63,64
Movement disorders were less prevalent among patients taking que-
tiapine, thus demonstrating the need for anti-Parkinson medication 
(n = 1117; four RCTs; RR 0.47; CI 0.4 to 0.6; NNT 4; CI 4 to 5; 
I2 88%) (Figure 15).37-51,65-82
Dry	mouth	(n	=	649;	two	RCTs;	RR	2.85;	CI	1.5	to	5.6;	NNH	
17; CI 7 to 65) and somnolence (n = 959; three RCTs; RR 1.51; CI 1.1 
to 2.2; NNH 18; CI 8 to 181) were more prevalent in the quetiapine 
group,	compared	with	typical	antipsychotics.	One	RCT	compared	que-
tiapine with risperidone, including 724 individuals with various psy-
chotic symptoms, and two-thirds had a diagnosis of schizophrenia or 
schizoaffective disorder. Around 30% of the patients dropped out of the 
study before its end (n = 728; one RCT; RR 0.94; CI 0.7 to 1.2). Four 
people, all treated with quetiapine, died during the study (n = 728; one 
RCT; RR 2.86; CI 0.2 to 52.8) (Figure 16).83,84
All the evaluations of mental state outcomes were continuous and 
showed no statistical differences between quetiapine and risperidone, 
including the following (Figure 17):83,84
Figure 5. Efficacy of paliperidone versus placebo, in relation to improvements in general condition and disease symptoms.
Review: Paliperidone for the treatment of adults with schizophrenia 
Comparison: 1 PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSE versus PLACEBO (all short-term) 
Outcome: 3 Overall state: 1. No clinically important change
Study or subgroup Paliperidone 
n/N
Placebo 
n/N
Risk Ratio 
M-H,Fixed,95% CI
Weight Risk Ratio 
M-H,Fixed,95% CI
Davidson et al.28 194/359 98/120 36.0 % 0.66 [0.58, 0.75]
Kane et al.27 164/374 88/126 32.2 % 0.63 [0.53, 0.74]
Marder et al.30 109/222 69/105 22.9 % 0.75 [0.62, 0.91]
Tzimos et al.31 47/76 27/38 8.8 % 0.87 [0.67, 1.14]
Total (95% CI) 1031 389 100.0 % 0.69 [0.63, 0.75]
Total events: 514 (Paliperidone), 282 (Placebo)
Heterogeneity: Chi2 = 5.22, df = 3 (P = 0.16); I2 = 43%
Test for overall effect: Z = 8.52 (P < 0.00001)
0.5 1 2
Favours Paliperidone Favours Placebo
Review: Paliperidone for the treatment of adults with schizophrenia 
Comparison: 1 PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSE versus PLACEBO (all short-term) 
Outcome: 4 Overall state: 2. Relapse: recurrence of psychotic symptoms
Study or subgroup Paliperidone 
n/N
Placebo 
n/N
Risk Ratio 
M-H,Fixed,95% CI
Weight Risk Ratio 
M-H,Fixed,95% CI
Davidson et al.28 24/364 11/123 22.9 % 0.74 [0.37, 1.46]
Kane et al.27 8/375 8/126 16.6 % 0.34 [0.13, 0.88]
Kramer et al.29 7/104 23/102 32.3 % 0.30 [0.13, 0.66]
Marder et al.30 14/224 13/106 24.5 % 0.51 [0.25, 1.05]
Tzimos et al.31 1/76 2/38 3.7 % 0.25 [0.02, 2.67]
Total (95% CI) 1143 495 100.0 % 0.45 [0.31, 0.66]
Total events: 54 (Paliperidone), 57 (Placebo)
Heterogeneity: Chi2 = 3.70, df = 4 (P = 0.45); I2 = 0.0%
Test for overall effect: Z = 4.11 (P < 0.000040)
0.2 0.5 1 2 5
Favours Paliperidone Favours Placebo
Figure 6. Efficacy of paliperidone versus placebo, in relation to recurrence of psychosis. 
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Reviews: Paliperidone for the treatment of adults with schizophrenia
Comparison: 3 PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus OLANZAPINE (fixed dose 10mg/day, all short-term)
Outcome: 1 Leaving the study early
Study or subgroup Paliperidone
n/N
Olanzapine
n/N
Risk Ratio
M-H, Fixed, 95% CI
Weight Risk Ratio
M-H, Fixed, 95% CI
I any reason
Davidson et al.28 137/367 40/128 30.2% 1.19 [0.89, 1.60]
Kane et al.27 108/375 38/128 28.8% 0.97 [0.71, 1.32]
Marder et al.30 119/224 60/110 41.0% 0.97 [0.79, 1.20]
Subtotal (95% CI) 966 366 100.0% 1.04 [0.89, 1.21]
Total events: 364 (Paliperidone), 138 (Olanzapine)
Heterogeneity: Chi2 = 1.45, df = 2 (P = 0.49); I2 = 0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
2 adverse event
Davidson et al.28 13/367 5/128 23.5% 0.91 [0.33, 2.49]
Kane et al.27 20/375 9/128 42.5% 0.76 [0.35, 1.62]
Marder et al.30 14/224 8/110 34.0% 0.86 [0.37, 1.99]
Subtotal (95% CI) 966 366 100.0% 0.83 [0.51, 1.35]
Total events: 47 (Paliperidone), 22 (Olanzapine)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 = 0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
3 lack of efficacy
Davidson et al.28 68/367 16/128 28.2% 1.48 [0.89, 2.46]
Kane et al.27 52/375 19/128 33.6% 0.93 [0.57, 1.52]
Marder et al.30 42/224 24/110 38.2% 0.86 [0.55, 1.34]
Subtotal (95% CI) 966 366 100.0% 1.06 [0.81, 1.40]
Total events: 162 (Paliperidone), 59 (Olanzapine)
Heterogeneity: Chi2 = 2.79, df = 2 (P = 0.25); I2 = 28%
Test for overall effect: Z = 0.42 (P = 0.68)
4 loss to follow up
Davidson et al.28 3/367 3/128 28.7% 0.35 [0.07, 1.71]
Kane et al.27 3/375 2/128 19.3% 0.51 [0.09, 3.03]
Marder et al.30 18/224 6/110 52.0% 1.47 [0.60, 3.61]
Subtotal (95% CI) 966 366 100.0% 0.96 [0.49, 1.91]
Total events: 24 (Paliperidone), 11 (Olanzapine)
Heterogeneity: Chi2 = 2.92, df = 2 (P = 0.23); I2 = 32%
Test for overall effect: Z = 0.10 (P = 0.92)
5 non compliance
Davidson et al.28 3/367 1/128 23.2% 1.05 [0.11, 9.97]
Kane et al.27 0/375 1/128 34.9% 0.11 [0.00, 2.79]
Marder et al.30 3/224 2/110 41.9% 0.74 [0.12, 4.34]
Subtotal (95% CI) 966 366 100.0% 0.59 [0.18, 1.94]
Total events: 6 (Paliperidone), 4 (Olanzapine)
Heterogeneity: Chi2 = 1.32, df = 2 (P = 0.52); I2 = 0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
6 unspecified participant reason
Davidson et al.28 43/367 11/128 35.0% 1.36 [0.73, 2.56]
Kane et al.27 28/375 5/128 16.0% 1.91 [0.75, 4.85]
Marder et al.30 40/224 17/110 49.0% 1.16 [0.69, 1.94]
Subtotal (95% CI) 966 366 100.0% 1.35 [0.93, 1.95]
Total events: 111 (Paliperidone), 33 (Olanzapine)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.64); I2 = 0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
7 unspecified reason
Davidson et al.28 7/367 4/128 51.8% 0.61 [0.18, 2.05]
Kane et al.27 5/375 1/128 13.0% 1.71 [0.20, 14.47]
Marder et al.30 2/224 3/110 35.2% 0.33 [0.06, 1.93]
Subtotal (95% CI) 966 366 100.0% 0.65 [0.27, 1.57]
Total events: 14 (Paliperidone), 8 (Olanzapine)
Heterogeneity: Chi2 = 1.37, df = 2 (P = 0.50); I2 = 0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
8 withdrawal of consent
Davidson et al.28 43/367 11/128 100.0% 1.36 [0.73, 2.56]
Subtotal (95% CI) 367 128 100.0% 1.36 [0.73, 2.56]
Total events: 43 (Paliperidone), 11 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
0.2 0.5 1 2 5
Favours  Paliperidone Favours Olanzapine
Figure 7. Efficacy of paliperidone versus olanzapine, in relation to improvement of symptoms over a six-week period.
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•	 reduced	average	PANSS	score	(n	=	637;	one	RCT;	MD,	mean	dif-
ference, 1.2; CI -2.0 to 4.4); 
•	 reduction	in	PANSS	subscale	of	positive	symptoms	(n	=	639;	one	
RCT;	MD	0.70;	CI	-0.2	to	1.6);
•	 reduction	in	PANSS	subscale	of	negative	symptoms	(n	=	641;	one	
RCT;	MD	0.30;	CI	-0.8	to	1.4).
Extrapyramidal adverse events occurred less frequently in subjects 
receiving quetiapine than in subjects receiving risperidone, thus dem-
onstrating the need for anti-Parkinson medication (n = 712; one RCT; 
RR 0.27; CI 0.2 to 0.5; NNT 11; CI 10 to 16), and in terms of the in-
cidence of events (n = 712; one RCT; RR 0.73; CI 0.6 to 0.9; NNT 10; 
CI 6 to 28) (Figure 18).83,84
The following adverse events were more common with quetiapine 
than with risperidone:
•	 dizziness	(n	=	728;	one	RCT;	RR	1.85;	CI	1.0	to	3.3;	NNH	18;	CI	
7 to 487);
•	 dry	mouth	(n	=	728;	one	RCT;	RR	2.11;	CI	1.2	to	3.8;	NNH	14;	
CI 6 to 82);
•	 drowsiness	(n	=	728;	one	RCT;	RR	2.03;	CI	1.4	to	2.9;	NNH	7;	CI	
4 to 17). 
Conclusions from review 
Quetiapine is effective for treating schizophrenia, but not very dif-
ferent from typical antipsychotics or risperidone in terms of efficacy and 
relapse prevention, but it has a lower risk of movement disorders and 
higher risk of dizziness, dry mouth and drowsiness. There was a recom-
mendation for further studies to evaluate the effectiveness of this drug. 
Studies on refractory schizophrenia
Despite	an	extensive	search	of	the	literature,	only	two	RCTs	includ-
ing patients with refractory episodes were found to have evaluated que-
tiapine. In the study by Conley et al.,85 a comparison was made between 
risperidone (4 mg/day), quetiapine (400 mg/day) and fluphenazine (12.5 
mg/day) over a 12-week period on a sample of 38 individuals. The drop-
out rate from treatment was greater with fluphenazine (69%) than with 
risperidone (31%) and quetiapine (42%). The criterion of response to 
treatment (reduction in BPRS scale > 20%) was achieved by 23% of those 
taking risperidone, 25% with quetiapine and 15% with fluphenazine.
Genç et al.86 reported on an RCT that evaluated 56 patients who 
were resistant to treatment and partially responsive to clozapine. The 
combination of clozapine plus amisulpride was compared with clozap-
ine plus quetiapine. At the end of eight weeks of study, both groups im-
Review: Paliperidone for the treatment of adults with schizophrenia
Comparison: 3 PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus OLANZAPINE (fixed dose 10mg/day, all short-term)
Outcome: 18 Adverse effect: 7a. Movement disorder - various
Study or subgroup Paliperidone n/N Olanzapine n/N Risk Ratio 
M-H, Fixed, 95% CI
Weight Risk Ratio 
M-H, Fixed, 95% CI
1 extrapyramidal disorder
Davidson et al. 28 30/364 4/127 51.1% 2.62 [0.94, 7.28]
Kane et al. 27 26/375 2/128 25.7% 4.44 [1.07, 18.43]
Marder et al. 30 9/224 2/109 23.2% 2.19 [0.48, 9.96]
Subtotal (95% CI) 963 364 100.0% 2.99 [1.44, 6.18]
Total events: 65 (paliperidone), 8 (olanzapine)
Heterogeneity: Chi2 = 0.52, df = 2 (P = 0.77); I2 = 0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
2 hyperkinesia
Davidson et al. 28 29/364 2/127 25.2% 5.06 [ 1.22, 20.90]
Kane et al. 27 25/375 5/128 63.4% 1.71 [0.67, 4.36]
Marder et al. 30 14/224 1/109 11.4% 6.81 [ 0.91, 51.14]
Subtotal (95% CI) 963 364 100.0% 3.14 [1.53, 6.42]
Total events: 68 (paliperidone), 8 (olanzapine)
Heterogeneity: Chi2 = 2.62, df = 2 (P = 1.00); I2 = 0.0%
Test for overall effect: Z = 3.12 (P = 0.0018)
3 hypertonia
Kane et al. 27 13/375 0/128 52.6% 9.26 [0.55, 154.72]
Marder et al. 30 9/224 0/109 47.4% 9.29 [0.55, 158.14]
Subtotal (95% CI) 599 237 100.0% 9.28 [1.26, 68.51]
Total events: 22 (paliperidone), 0 (olanzapine)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 = 0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
0.1 1 10
favours risperidone favours olanzapine
Figure 8. Paliperidone versus olanzapine, in relation to adverse effects.
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proved significantly, but the improvement was greater with amisulpride 
than with quetiapine. This difference in favor of amisulpride was shown 
from the third week onwards in assessments on the CGI scale, and from 
the sixth week onwards using the BPRS, SANS and SAPS rating scales. 
The two association strategies were well tolerated.
RISPERIDONE FOR TREATING REFRACTORY 
SCHIZOPHRENIA
Risperidone is a benzisoxazole derivative, with a strong blocking ef-
fect	on	D2	and	5-HT2	receptors.	It	binds	to	a1,	a2	and	H1	receptors,	
and	is	also	a	potent	LSD	(lysergic	acid	diethylamide)	antagonist.	It	is,	
however, virtually devoid of anticholinergic effects.
Cochrane review of risperidone versus typical antipsychotics for treating 
schizophrenia
The review by Hunter et al.13 included 23 RCTs with 4,445 indi-
viduals, and evaluated the effectiveness of risperidone versus typical an-
tipsychotics	for	treating	schizophrenia.	Over	the	short	term,	risperidone	
was more effective in reducing positive and negative symptoms, accord-
ing to PANSS, compared with haloperidol (n = 2368; nine RCTs; RR 
0.72; CI, 20% did not improve, 0.59 to 0.88; NNT 8) (Figure 19).87-97 
The favorable outcome for risperidone was also sustained in long-
term studies (n = 859, 2RCTs RR, 20% did not improve, 0.51 CI; 0.38 
to 0.67; NNT 4; n = 675; one RCT; RR, not improved 40%, 0.75; CI 
0.66 to 0.84; NNT 5; n = 675, one RCT; RR, 60% not improved, 0.90; 
CI 0.84 to 0.96; NNT 11). A follow-up on the patients performed one 
year after administering risperidone also found a lower recurrence rate, 
compared with haloperidol use (n = 367; one RCT; RR 0.64; CI 0.41 
to 0.99; NNT 7). Patients taking risperidone showed significantly fewer 
movement disorders overall (including extrapyramidal side effects) than 
did those receiving older typical antipsychotics (n = 2702; 10 RCTs; RR 
0.63; CI 0.56 to 0.71; NNT 3). The number of patients taking antipar-
kinsonian drugs was significantly lower in the risperidone group (n = 
2524; 11 RCTs; RR 0.66; CI 0.58 to 0.74; NNT 4). In relation to body 
weight, four studies (n = 1708) found a higher propensity for weight 
gain among patients using risperidone, compared with those taking typ-
ical antipsychotics (RR 1.55; CI 1.25 to 1.93; NNH 3).
Review: Quetiapine for schizophrenia
Comparison: 1 QUETIAPINE (any dose) versus PLACEBO (all short-team data)
Outcome: 1 Leaving the study early
Study os subgroup Treatment 
n/N
Control 
n/N
Risk Ratio 
M-H, Fixed , 95% CI
Weight Risk Ratio 
M-H,Fixed, 95% CI
1 any cause
Europe-USA34-36 102/190 57/96 44.9% 0.90 [0.73, 1.12]
North America37-51 143/258 35/51 34.6% 0.81 [0.65, 1.00]
USA52 0/8 1/4 1.1% 0.19 [0.01, 3.75]
USA53-55 26/54 33/55 19.4% 0.80 [0.56, 1.14]
Subtotal (95% CI) 510 206 100.0% 0.84 [0.73, 0.97]
Total events: 271 (Treatment), 126 (Control)
Heterogeneity: Chi2 = 1.62, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
2 due to adverse events
Europe-USA34-36 14/190 3/96 42.8% 2.36 [0.69, 8.01]
North America37-51 1/258 2/51 35.9% 0.10 [0.01, 1.07]
USA52 0/8 0/4 0.0% Not estimable
USA53-55 3/54 2/55 21.3% 1.53 [0.27, 8.79]
Subtotal (95% CI) 2510 206 100.0% 1.37 [0.60, 3.12]
Total events: 18 (Treatment), 7 (Control)
Heterogeneity: Chi2 = 5.45, df = 2 (P = 0.07); I2 = 63%
Test for overall effect: Z = 0.75 (P = 0.45)
3 due to tratment failure
Europe-USA34-36 59/190 42/96 41.5% 0.71 [0.52, 097]
North America37-51 107/258 30/51 37.2% 0.71 [0.54, 0.93]
USA52 0/8 1/4 1.4% 0.19 [0.01, 3.75]
USA53-55 16/54 27/55 19.9% 0.60 [0.37, 0.99]
Subtotal (95% CI) 510 206 100.0% 0.68 [0.56, 0.82]
Total events: 182 (Treatment), 100 (Control)
Heterogeneity: Chi2 = 1.09, df = 3 (P = 0.78); I2 = 0.0%
Test for overall effect: Z = 3.94 (P = 0.000080)
0.2 0.5 1 2 5
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Figure 9. Quetiapine versus placebo, in relation to dropout rate in the study.
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Review: Quetiapine for schizophrenia
Comparison: 3 QUETIAPINE (any dose) versus CLASSICAL ANTIPSYCHOTICS - short & medium-term data
Outcome: 3 Overall state: Average change (CGI, low score = good)
Study or subgroup Treatment 
N
Mean (SD) Control 
N
Mean (SD) Mean Difference 
IV, Fixed, 95% CI
Mean Difference 
IV, Fixed, 95% CI
1 short-term
Canada64, 65 11 -2 (1.61) 7 -0.71 (0.49) -1.29 [-2.31, -0.27]
Multi-country65-69 220 -0.92 (1.33) 219 -1.17 (1.18) 0.25 [0.01, 0.49]
North America37-51 255 -0.45 (1.1) 50 -0.69 (1.13) 0.24 [-0.10, 0.58]
Subtotal (95% CI) 486 276 0.19 [0.00, 0.38]
Heterogeneity: Chi2 = 8.45, df = 2 (P = 0.01); I2 = 76% 
Test for overall effect: Z = 1.99 (P = 0.047)
-4 -2 0 2 4
favours treatment favours control
Figure 12. Efficacy of quetiapine versus classic antipsychotics, in relation to overall state, over the short and medium terms.
Review: Quetiapine for schizophrenia
Comparison: 2 >/= 250mg/day QUETIAPINE versus < 250 mg/day QUERIAPINE - all short-term data
Outcome: 1 Leaving the study early
Study or subgroup Treatment 
n/N
Control 
n/N
Risk Ratio M-H, Fixed, 
95% CI
Weight Risk Ratio M-H, Fixed, 95% CI
1 any cause
Europe-USA 34-36 48/96 54/94 18.9% 0.87 [0.67, 1.13]
Multi-country 56-62 195/409 119/209 54.5% 0.84 [0.72, 0.98]
North America 37-51 80/157 63/101 26.6% 0.82 [0.66, 1.01]
Subtotal (95% CI) 662 404 100.0% 0.84 [0.75, 0.94]
Total events: 323 (Treatment), 236 (Control) 
Heterogeneity: Chi2 = 0.13, df = 2 (P = 0.94); I2 = 0.0% 
Test for overall effect: Z = 3.03 (P = 0.0024)
2 due to adverse event
Europe-USA 34-36 7/96 7/94 41.7% 0.98 [0.36, 2.68]
Multi-country 56-62 19/409 7/209 54.7% 1.39 [0.59, 3.25]
North America 37-51 1/157 0/101 3.6% 1.94 [0.08, 47.08]
Subtotal (95% CI) 662 404 100.0% 1.24 [0.66, 2.33]
Total events: 27 (Treatment), 14 (Control) 
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 = 0.0% 
Test for overall effect: Z = 0.66 (P = 0.51)
3 due treatment failure
Europe-USA 34-36 25/96 34/94 18.2% 0.72 [0.47, 1.11]
Multi-country 56-62 124/409 80/209 56.0% 0.79 [0.63, 0.99]
North America 37-51 57/157 40/101 25.8% 0.92 [0.67, 1.26]
Subtotal (95% CI) 662 404 100.0% 0.81 [0.68, 0.96]
Total events: 206 (Treatment), 154 (Control) 
Heterogeneity: Chi2 = 0.91, df = 2 (P = 0.64); I2 = 0.0% 
Test for overall effect: Z = 2.42 (P = 0.015
0.5 1 2
favours treatment favours control
Figure 10. Higher doses of quetiapine (≥ 250 mg/day) versus lower doses of quetiapine (< 250 mg/day), in relation to dropout rate in the study.
Review: Quetiapine for schizophrenia
Comparison: 2 >/=  250 mg/day QUETIAPINE versus < 250 mg/day QUETIAPINE - all short-term data
Outcome: 5 Mental state: 1. No important improvement (BPRS or PANSS)
Study or subgroup Treatment
n/N
Control
n/N
Risk Ratio
M-H, Fixed, 95% CI 
Weight Risk Ratio
M-H, Fixed, 95% CI
Europe-USA34-36 40/96 48/94 19.3% 0.94 [0.70, 1.25]
Multi-country56-62 184/409 98/209 51.6% 0.96 [0.80, 1.15]
North America37-51 80/157 60/101 29.1% 0.86 [0.69, 1.07]
Total (95% CI) 662 404 100.0% 0.93 [0.82, 1.05]
Total events: 310 (Treatment), 206 (Control)
Heterogeneity: Chi2 = 0.61, df = 2 (P = 0.74);I2 = 0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
0.7 1 1.5
favours treatment favours control
Figure 11. Higher doses of quetiapine (≥ 250 mg/day) versus lower doses of quetiapine (< 250 mg/day), in relation to mental state and lack of 
significant improvement.
Sao Paulo Med J. 2010; 128(3):141-66
Melnik T, Soares BG, Puga MES, Atallah AN
154
There was no difference between the two drugs regarding the num-
ber of patients with erectile dysfunction (n = 106; two RCTs; RR 1.55; 
CI 0.58 to 4.20). Some studies have shown that patients who took ris-
peridone reported rhinitis more frequently than did those taking con-
ventional antipsychotics (n = 656; three RCTs; RR 1.99; CI 1.24 to 
3.19; NNH 3). 
Conclusions from review 
Risperidone appears to be more acceptable for patients with schizo-
phrenia than are typical antipsychotics. The side effects are less frequent 
compared with haloperidol. The benefits achieved with risperidone 
should be analyzed taking its higher cost into consideration, as well as 
its tendency to promote weight gain. Recent data regarding the reduc-
tion of relapse rates with risperidone over the long term, compared with 
typical antipsychotics, need to be replicated in other studies. 
Cochrane review of risperidone versus atypical antipsychotics for treating 
schizophrenia
The systematic review by Gilbody et al.14 included nine studies 
comparing risperidone with clozapine (five studies involving patients 
with criteria for refractory schizophrenia), olanzapine (three studies) 
and amisulpride (one study). The dropout rates were high. The total 
PANSS	scores	were	not	significantly	different	(n	=	134;	DMP	2.0;	CI	
-3.04-6.97) in the assessment six weeks after starting the treatment, and 
studies that had sufficient data to allow evaluations on segregated posi-
tive and negative subscales showed no significant difference (PANSS 
Review: Quetiapine for schizophrenia
Comparison: 3 QUETIAPINE (any dose) versus CLASSICAL ANTIPSYCHOTICS - short & medium-term data
Outcome: 4 mental state: 1. No important improvement (BPRS or PANSS) - short term only
Study or subgroup Treatment 
n/N
Control 
n/N
Risk Ratio M-H,Fixed,  95% CI Weight Risk Ratio M-H,Fixed,  
95% CI
Africa-Europe70,71 35/101 48/100 16.9% 0.72 [0.52, 1.01]
Multi-country65-69 124/221 120/227 41.6% 1.06 [0.90, 1.26]
Multi-country72-80 69/143 77/145 26.9% 0.91 [0.72, 1.14]
North America37-51 140/258 25/52 14.6% 1.13 [0.83, 1.53]
Total (95% CI) 723 524 100.0% 0.97 [0.87, 1.09]
Total events: 368 (Treatment), 270 (Control)
Heterogeneity: Chi2 = 5.29, df = 3 (P = 0.15); I2 = 43% 
Test for overall effect: Z = 0.46 (P = 0.64)
0.5 1 2
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Figure 13. Efficacy of quetiapine versus classic antipsychotics, in relation to mental state and lack of significant improvement, over the short and medium terms.
Review: Quetiapine for schizophrenia
Comparison: 3 QUETIAPINE (any dose) versus CLASSICAL ANTIPSYCHOTICS - short &medium-term data
Outcome: 7 Mental state: 4. Average change in negative symptoms (low score = good)
Study or subgroup Treat-
ment N
Mean (SD) Control 
N
Mean (SD) Mean Difference IV, Fixed, 95% CI Weight Mean Difference IV, Fixed, 95% CI
1 SANS - short-term
North America37-51 255 -0.89 (3.74) 50 -1.83 (3.61) 100.0% 0.94 [-0.16, 2.04]
Subtotal (95% CI) 255 50 100.0% 0.94 [-0.16, 2.04]
Heterogeneity: not applicable 
Test for overall effect: Z = 2.49 (P = 0.094)
2 PANSS negative subscale - 
short-term
Canada64,65 11 -7.64 (7.13) 7 -1.57 (3.05) 100.0% -6.07 [-10.85, -1.29]
Subtotal (95% CI) 11 7 100.0% -6.07 [-10.85, -1.29]
Heterogeneity: not applicable 
Test for overall effect: Z = 2.49 (P = 0.013)
3 PANSS negative subscale - 
medium-term
Canada64,65 13 -5.23 (7.37) 12 -2.08 (4.34) 100.0% -3.15 [ -7.85, 1.55]
Subtotal (95% CI) 13 12 100.0% -3.15 [ -7.85, 1.55]
Heterogeneity: not applicable 
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 10.15, df = 2 (P = 0.01), I2 = 80%
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Figure 14. Efficacy of quetiapine versus classic antipsychotics, in relation to mental state and average change in negative symptoms.
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Review: Quetiapine for schizophrenia
Comparison: 3 QUETIAPINE (any dose) versus CLASSICAL ANTIPSYCHOTICS - short & medium-term data
Outcome: 8 Adverse effects: 1. Movement disorders
Study or subgroup Treatment 
n/N
Control n/N Risk Ratio M-H, Fixed,
 95% CI
Weight Risk Ratio M-H,Fixed, 
95% CI
1 patients receiving medications for 
extrapyramidal adverse effects
Africa-Europe70,71 10/101 15/100 5.7% 0.66 [0.31, 1.40]
Japan81,82 21/90 55/90 20.7% 0.38 [0.25, 0.57]
Multi-country65-69 29/221 111/227 41.2% 0.27 [0.19, 0.39]
Multi-country72-80 63/143 87/145 32.5% 0.73 [0.58, 0.92]
Subtotal (95% CI) 555 562 100.0% 0.47 [0.39, 0.55]
Total events: 123 (Treatment), 268 (Control)
Heterogeneity: Chi2 = 25.93, df = 3 (P < 0.00001); I2 = 88%
Test for overall effect: Z = 8.65 (P < 0.00001)
2 parkinsonism
Multi-country65-69 18/221 77/227 75.3% 0.24 [0.15, 0.39]
North America37-51 13/258 15/52 24.7% 0.17 [0.09, 0.34]
Subtotal (95% CI) 479 279 100.0% 0.22 [0.15, 0,33]
Total events: 31 (Treatment), 92 (Control)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 = 0.0%
Test for overall effect: Z = 7.31 (P < 0.00001)
3 akathisia
Africa-Europe70, 71 5/101 14/100 16.4% 0.35 [0.13, 0.94]
Multi-country65-69 11/221 46/227 53.0% 0.25 [0.13, 0.46]
Multi-country72-80 8/143 13/145 15.1% 0.62 [0.27, 1.46]
North America37-51 3/258 8/52 15.5% 0.08 [0.02, 0.28]
Subtotal (95% CI) 723 524 100.0% 0.29 [0.19, 0.44]
Total events: 27 (Treatment), 81 (Control)
Heterogeneity: Chi2 = 7.70, df = 3 (P = 0.05); I2 = 61%
Test for overall effect: Z = 5.82 (P < 0.00001)
4 dystonia
Africa-Europe70, 71 1/101 1/100 5.2% 0.99 [0.06, 15.61]
Multi-country65-69 1/221 17/227 86.3% 0.06 [0.01, 0.45]
North America37-51 2/258 1/52 8.6% 0.40 [0.04, 4.36]
Subtotal (95% CI) 580 379 100.0% 0.14 [0.04, 0.49]
Total events: 4 (Treatment), 19 (Control)
Heterogeneity: Chi2 = 3.39, df = 2 (P = 0.18); I2 = 41%
Test for overall effect: Z = 3.90 (P = 0.0020)
0.2 0.5 1 2 5
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Figure 15. Quetiapine versus classic antipsychotics, in relation to movement disorders (adverse effects), over the short and medium terms.
positive	scale,	n	=	134;	DMP	1.359;	CI	-0.581	to	3.320;	PANSS	and	
BPRS	negative	 symptoms	 subscale,	n	=	134;	DMP	 -0.17;	CI	 -0.521	
to 0.163). The wide confidence intervals did not allow assignation of 
equivalence between risperidone and clozapine, or determination of su-
periority	 of	 either	 of	 these	drugs.	Overall	 scores,	 as	measured	on	 the	
CGI	scale,	showed	no	differences	between	the	groups	(n	=	105;	DMP	
0.00; CI -0.46 to 0.47). There was no difference over the short term in 
relation to tolerance to treatment, reported by patients using clozapine 
and risperidone (n = 466; RR 1.00; CI 0.73 to 1.37). 
Olanzapine	and	risperidone	appear	to	be	very	similar	with	regard	
to the number of patients who responded to treatment (40% reduction 
in PANSS, n = 339; RR 1.14; CI 0.99 to 1.32). Patients taking olan-
zapine adhered better to the study protocol (n = 404; RR 1.31; CI 1.06 
to 1.60; NNT 8; CI 4 to 32) and had fewer side effects and extrapy-
ramidal effects (n = 339; RR 1. 67; CI 1.14 to 2.46; NNH 8; CI 5 to 
33) although the doses of risperidone administered were higher than 
those recommended in practice. The doses administered in these studies 
ranged from 1 mg/day to 16 mg/day. In one study (n = 228), amisul-
pride seemed to be very similar to risperidone in most parameters. No 
useful data was presented regarding the cost of treatment. The data pre-
sented on quality of life was also very scarce. 
Conclusions from review
Equivalence between clozapine and risperidone for treating refrac-
tory schizophrenia may not yet have been established. There seem to be 
few differences between olanzapine, risperidone and amisulpride. The 
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Review: Quetiapine for schizophrenia
Comparison: 4 QUETIAPINE (any dose) versus RISPERIDONE (any dose) - all medium-term data
Outcome: 1 Leaving the study early
Study or subgroup Treatment 
n/N
Control 
n/N
Risk Ratio M-H, Fixed, 
95% CI
Weight Risk Ratio 
M-H, Fixed, 95% CI
1 any cause
USA83,84 176/553 59/175 100.0% 0.94 [0.74, 1.20]
Subtotal (95% CI) 553 175 100.0% 0.94 [0.74, 1.20]
Total events: 176 (Treatment), 59 (Control) 
Heterogeneity: not applicable 
Test for overall effect: Z = 0.47 (P = 0.64)
2 due to adverse events
USA 83,84 48/553 9/175 100.0% 1.69 [0.85, 3.37]
Subtotal (95% CI) 553 175 100.0% 1.69 [ 0.85, 3.37]
Total events: 48 (Treatment), 9 (Control) 
Heterogeneity: not applicable 
Test for overall effect: Z = 1.48 (P = 0.14)
3 due to treatment failure
USA 83,84 32/553 18/175 100.0% 0.56 [ 0.32, 0.98]
Subtotal (95% CI) 553 175 100.0% 0.56 [ 0.32, 0.98]
Total events: 32 (Treatment), 18 (Control) 
Heterogeneity: not applicable 
Test for overall effect: Z = 2.04 (P = 0.041)
0.2 0.5 1 2 5
favours treatment favours control
Figure 16. Quetiapine versus risperidone, in relation to dropout rate in the study.
Review: Quetiapine for schizophrenia
Comparison: 4 QUETIAPINE (any dose) versus RISPERIDONE (any dose) - all medium-term data
Outcome: 3 Mental state: 1. Average change (PANSS, low score = good)
Study or subgroup Treat-
ment N
Mean (SD) Control 
N
Mean (SD) Mean Difference IV, Fixed, 95% CI Weight Mean Difference IV, Fixed, 
95% CI
USA83,84 489 13 (20.79) 148 11.8 (15.82) 100.0% 1.20 [-1.95, 4.35]
Total (95% CI) 489 148 100.0% 1.20 [-1.95, 4.35]
Heterogeneity: not applicable 
Test for overall effect: Z = 0.75 (P = 0.45)
-10 -5 0 5 10
Favours treatment Favours control
Figure 17. Quetiapine versus risperidone, in relation to mental state and average change.
Review: Quetiapine for schizophrenia
Comparison: 4 QUETIAPINE (any dose) versus RISPERIDONE (any dose) - all medium-term data
Outcome: 6 Adverse effects: 1. Movement disorders
Study or subgroup Treatment
n/N
Control
n/N
Risk Ratio
M-H, Fixed, 95% CI 
Weight Risk Ratio
M-H, Fixed, 95% CI
1 patients receiving medications for extrapyramidal adverse effects
USA83,84 19/541 22/171 100.0% 0.27 [0.15, 0.49]
Subtotal (95% CI) 541 171 100.0% 0.27 [0.15, 0.49]
Total events: 19 (Treatment), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.32 (P = 0.000016)
2 patients with clinically significant extrapyramidal adverse effects
USA83,84 161/541 70/171 100.0% 0.73 [0.58, 0.91]
Subtotal (95% CI) 541 171 100.0% 0.73 [0.58, 0.91]
Total events: 161 (Treatment), 70 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
0.2 0.5 1 2 5
favours treatment favours control
Figure 18. Quetiapine versus risperidone, in relation to movement disorders (adverse effects).
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studies available are limited in many ways: lacking long-term follow-
up, clinically relevant parameters, and assessment of quality of life. For 
individuals with mild schizophrenia, risperidone is an effective antip-
sychotic, but can cause movement disorders and more side effects than 
other new drugs such as olanzapine, although this figure was based on 
a trial from a study using higher doses of risperidone than those used 
in	clinical	practice.	Olanzapine,	risperidone	and	clozapine	tend	to	lead	
to weight gain, while risperidone may be preferable. More research is 
needed to confirm these findings. In cases of refractory schizophrenia, 
clozapine is often offered as an alternative but it has significant side ef-
fects that require weekly laboratory monitoring. Risperidone does not 
appear to be as acceptable as clozapine regarding occurrences of move-
ment disorders, and this is the only reason clozapine is usually offered 
after risperidone. However, there is still insufficient evidence to suggest 
that risperidone is as effective as clozapine for symptoms refractory to 
typical antipsychotics.
Cochrane review of risperidone compared with olanzapine for treating 
schizophrenia
Over	the	short	term,	no	difference	was	found	between	risperidone	
and olanzapine with regard to symptom improvement (n = 548; two 
RCTs; RR 1.00; CI 0.88 to 1.15).15	One	 study	 showed	 favorable	 re-
Review: Risperidone versus typical antipsychotic medication for schizophrenia 
Comparison: 1 RISPERIDONE vs TYPICAL NEUROLEPTIC MEDICATION 
Outcome: 3 Overall state: 3. Not improved to a clinically important degree (no greater than 20% change in PANSS score)
Study or subgroup Treatment 
n/N
Control 
n/N
Risk Ratio 
M-H, Fixed, 95% CI
Weight Risk Ratio 
M-H, Fixed, 95% CI
1 short-term (up to 12 weeks)
Blin et al.87 4/21 8/20 1.2 % 0.48 [0.17, 1.34]
Chouinar et al.88 44/92 11/21 2.7 % 0.91 [0.58, 1.45]
Claus et al.89 15/22 17/22 2.6 % 0.88 [0.61, 1.27]
Hoyberg et al.90 18/55 22/52 3.4 % 0.77 [0.47, 1.27]
Huttunen et al.91 20/48 29/50 4.3 % 0.72 [0.48, 1.08]
Marder and Meibach et al.92 139/256 46/66 11.0 % 0.78 [0.64, 0.95]
Min et al.93 6/16 5/19 0.7 % 1.43 [0.53, 3.81]
Peuskens94 457/1136 97/226 24.4 % 0.94 [0.79, 1.11]
Potkin and Gutierres95 86/163 57/83 11.4 % 0.77 [0.63, 0.94]
Subtotal (95% CI) 1809 559 61.7 % 0.85 [0.77, 0.93]
Total events: 789 (treatment), 292 (Control)
Heterogeneity: Chi2 = 6.17, df = 8 (P = 0.63); I2  = 0.0%
Test for overall effect: Z = 3.32 (P = 0.00090)
2 long term (over 26 weeks)
Bouchard et al.96 65/93 77/91 11.7 % 0.83 [0.70, 0.97]
Mahmoud et al.97 126/349 170/326 26.5 % 0.69 [0.58, 0.82]
Subtotal (95% CI) 442 417 38.3 % 0.73 [0.65, 0.83]
Total events: 191 (treatment), 247 (Control)
Heterogeneity: Chi2 = 2.55, df = 1 (P = 0.11); I2  = 61%
Test for overall effect: Z = 4.74 (P < 0.00001)
Total (95% CI) 2251 976 100.0 % 0.80 [0.74, 0.87]
Total events: 980 (treatment), 539 (Control)
Heterogeneity: Chi2 = 9.66, df = 10 (P = 0.47); I2  = 0.0%
Test for overall effect: Z = 5.50 (P < 0.00001)
0.1 0.2 0.5 1.0 2.0 5.0 10.0
Favours treatment Favours control
Figure 19. Risperidone versus typical neuroleptic medication, in relation to overall state and lack of clinically significant degree of improvement.
Review: Risperidone versus olanzapine for schizophrenia
Comparison: 1 RISPERIDONE versus OLANZAPINE
Outcome: 1 Global effect: 1.Various outcomes
Study or subgroup Risperidone 
n/N
Olanzapine 
n/N
Risk Ratio M-H, Random, 
95% CI
Weight Risk Ratio M-H, Random, 
95% CI
4 long term (for 1 year) - relapse/hospitalisation
Namjoshi et al.98,99 39/136 19/143 100.0% 2.16 [1.31, 3.54]
Subtotal (95% CI) 136 143 100.0% 2.16 [1.31, 3.54]
Total events: 39 (Risperidone), 19 (Olanzapine)
Heterogeneity: not applicable 
Test for overall effect: Z = 3.04 (P = 0.0023)
0.1 0.2 0.5 1.0 2.0 5.0 10.0
favours risperidone favours olanzapine
Figure 20. Efficacy of risperidone versus olanzapine, in relation to relapse/hospitalization.
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sults with olanzapine regarding the outcome of relapse/rehospitaliza-
tion over a 12-month period, compared with risperidone (n = 279; one 
RCT; RR 2.16; CI 1.31 to 3.54; NNH 7; CI 3 to 25) (Figure 20).98,99 
There was no difference between risperidone and olanzapine regarding 
mental state parameters evaluated using the NSSHL scale (n = 552; two 
RCTs;	RR	“no	PANSS	decrease	of	20%	for	eight	weeks”,	1.01;	CI	0.87	
to 1.16) (Figure 21).100-102
Both drugs caused adverse events: 75% of the patients reported 
some event, and 20% reported anticholinergic symptoms. Both groups 
reported insomnia, although it was more frequent among patients tak-
ing risperidone (n = 1588; five RCTs; RR 1.41; CI 1.15 to 1.72; NNH 
15; CI 9 to 41) (Figure 22).100,101,103-105 About 30% of the patients re-
ported somnolence (n = 1713; six RCTs; RR 0.92; CI 0.79 to 1.07). 
With	 regard	 to	 extrapyramidal	 symptoms	 (n	=	893;	 three	RCTs;	RR	
1.18; CI 0.75 to 1.88), 25% of the subjects taking risperidone required 
the use of additional medication to relieve these symptoms (n = 419; 
two RCTs; RR 1.76; CI 1.25 to 2.48; NNH 8; CI 4 to 25). Patients 
taking risperidone were less prone to weight gain, compared with those 
taking	olanzapine.	Weight	gain	was	significant	(n	=	984;	two	RCTs;	RR	
“gain	of	more	than	7%	of	baseline	weight	over	the	short	term”,	0.47;	CI	
Review: Risperidone versus olanzapine for schizophrenia
Comparison: 1 RISPERIDONE versus OLANZAPINE
Outcome: 4 Mental: 1. No specific degree of response (as defined by PANSS total change)
Study or subgroup Risperidone Olanzapine Risk Ratio
M-H, Random, 95% CI
Weight Risk Ratio
M-H, Random, 95% CI
1 short term <20% decrease
Conley and Mahmound100 119/188 121/189 77.8% 0.99 [0.85, 1.15]
Jeste et al.101 39/87 37/88 22.2% 1.07 [0.76, 1.50]
Subtotal (95% CI) 275 277 100.0% 1.00 [0.87, 1.15]
Total events: 158 (Risperidone), 158 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 = 0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
 
2 short term <30% decrease
Jeste et al.101 48/87 49/88 100.0% 0.99 [0.76, 1.29]
Subtotal (95% CI) 87 88 100.0% 0.99 [0.76, 1.29]
Total events: 48 (Risperidone), 49 (Olanzapine)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
3 short term <40% decrease
Conley and Mahmound100 154/188 166/189 72.3% 0.93 [0.86, 1.02]
Jeste et al.101 59/87 61/88 27.7% 0.98 [0.80, 1.20]
Subtotal (95% CI) 275 277 100.0% 0.94 [0.87, 1.02]
Total events: 213 (Risperidone), 227 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 = 0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
4 long term <20% decrease
Tran et al.102 (HGBG) 63/167 70/172 100.0% 0.93 [0.71, 1.21]
Subtotal (95% CI) 167 172 100.0% 0.93 [0.71, 1.21]
Total events: 63 (Risperidone), 70 (Olanzapine)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
5 long term <30% decrease
Tran et al.102 (HGBG) 95/167 84/172 100.0% 1.16 [0.95, 1.43]
Subtotal (95% CI) 167 172 100.0% 1.16 [0.95, 1.43]
Total events: 95 (Risperidone), 84 (Olanzapine)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
6 long term <40% decrease
Tran et al.102 (HGBG) 123/167 111/172 100.0% 1.14 [0.99, 1.32]
Subtotal (95% CI) 167 172 100.0% 1.14 [0.99, 1.32]
Total events: 123 (Risperidone), 111 (Olanzapine)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
7 long term <50% decrease
Tran et al.102 (HGBG) 147/167 136/172 100.0% 1.11 [1.01, 1.22]
Subtotal (95% CI) 167 172 100.0% 1.11 [1.01, 1.22]
Total events: 147 (Risperidone), 136 (Olanzapine)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
0.5 0.7 1.0 1.5 2.0
Favours risperidone Favours olanzapine
Figure 21. Efficacy of risperidone versus olanzapine, in relation to mental state/no specific degree of response.
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0.36 to 0.61; NNH 7; CI 6 to 10) Patients taking risperidone were less 
likely to abandon treatment because of metabolic side effects and weight 
gain, compared with those taking olanzapine (n = 667; one RCT; RR 
0.19; CI 0.08 to 0.45) (Figure 23).100,102-104,106 
Patients taking risperidone more frequently presented ejaculation 
disorders (n = 370; two RCTs; RR 4.36; CI 1.38 to 13.76; NNH 20; 
CI 6 to 176). Both drugs were associated with high dropout rates over 
time: 66% in the risperidone group compared with 56% in the olan-
zapine group (n = 1440; five RCTs; RR 1.17; CI 1.08 to 1.27; NNH 
11; CI 7 to 23). 
Conclusions from review
Both drugs are associated with reducing the levels of psychotic 
symptoms.	One	study	showed	favorable	results	with	olanzapine	regard-
ing the outcome of relapse/rehospitalization over a 12-month period, 
compared	with	 risperidone.	Occurrences	of	 side	effects	were	 frequent	
with both drugs. Some differences were found in relation to the types 
of side effects. Risperidone and olanzapine are expensive drugs. Patients 
should be informed about the side effects. 
Cochrane review of long-acting injection of risperidone for treating 
schizophrenia
A systematic review published in the Cochrane Library107 evalu-
ated the effectiveness of long-acting risperidone injections for treating 
schizophrenia.	Only	one	study	(n	=	400)	was	found	comparing	risperi-
done with a placebo injection, but 56% of the patients did not complete 
the three-month study, thus rendering some of the data on the overall 
effect and mental state unusable. Injectable risperidone (25 mg, 50 mg 
and 75 mg) compared with placebo did not affect anxiety levels (n = 
400; RR 0.58; CI 0.32 to 1.05) but decreased agitation (n = 400; RR 
0.60; CI 0.39 to 0.92). Injectable risperidone did not significantly af-
fect hallucination episodes (n = 400; RR 1.23; CI 0.47 to 3.22), but the 
number of episodes of psychosis was diminished (n = 400; RR 0.52; CI 
0.33 to 0.83; NNT 9; CI 7 to 26) (Figure 24).108
The dropout rates were higher in the treatment group using inject-
able risperidone than in the placebo group (n = 400; RR 0.74; CI 0.63 
to 0.88; NNT 6; CI 4 to 12) (Figure 25).108
Severe side effects were common in both groups (13% to 23%), 
but more significant in the placebo group (n = 400; RR 0.59; CI 0.38 
to 0.93; NNT 11; CI 7 to 70). However, incomplete records made the 
data difficult to interpret. Movement disorders were common in both 
groups (n = 400; RR 2.38; CI 0.73 to 7.78), although it seemed that 
they were more frequent among patients taking injectable risperidone 
at	higher	doses.	Only	one	study	(n	=	640)	compared	injectable	risperi-
done to oral risperidone among patients with mild schizophrenia. For 
the overall state, there were no differences between the two approaches 
(n	=	640;	RR	“no	overall	improvement”	1.06;	CI	0.92	to	1.22).	Men-
tal	state	measurements	were	also	similar	between	the	groups.	Just	over	
half of both groups reported adverse events (n = 640; RR 1.04; CI 0.91 
to 1.18).
Conclusions from review
This review identified only two studies. It was concluded that among 
less stable patients, the need for regular oral doses could be avoided 
through the use of injectable risperidone, although the events are still 
not well reported. In severe cases of schizophrenia, some benefits are ob-
vious, with increased rates of adherence to treatment with injectable ris-
peridone, compared with placebo. 
Studies on refractory schizophrenia
Four RCTs assessing risperidone for treating refractory schizophre-
nia were included in the new search. Suzuki et al.109 evaluated the effec-
tiveness of an antipsychotic polypharmacy regimen for treating refracto-
ry schizophrenia. Seventeen patients with refractory schizophrenia who 
did not respond to a monotherapy sequence of olanzapine, quetiapine 
and risperidone were subsequently treated with combination therapy 
consisting of olanzapine plus risperidone for at least eight weeks. Seven 
patients responded to the combination treatment in accordance with 
the primary endpoint, which was defined as post-treatment measure-
ments on the BPRS of less than 70% of the pretreatment values. These 
patients were classified as such, on average 10 weeks after starting polyp-
harmacy. Two were successful in subsequent conversion to monother-
apy. None of the patients stopped treatment prematurely. The overall 
functioning assessment score improved from 37.1 to 53.0 among the 
Review: Risperidone versus olanzapine for schizophrenia
Comparison: 1 RISPERIDONE versus OLANZAPINE
Outcome: 13 Adverse events: 3c. Central nervous system - sleep problems
Study or subgroup Risperidone
n/N
Olanzapine
n/N
Risk Ratio
M-H, Random, 95% CI 
Weight Risk Ratio
M-H, Random, 95% CI
3 insomnia
CATIE103 83/341 55/336 34.0% 1.49 [1.10, 2.02]
Conley and Mahmoud100 45/188 35/189 26.7% 1.29 [0.87, 1.91]
Jeste et al.101 14/87 9/88 10.2% 1.57 [0.72, 3.44]
Keefe et al.104 36/158 26/159 22.6% 1.39 [0.89, 2.19]
Purdon et al.105 6/21 5/21 6.5% 1.20 [0.43, 3.33]
Subtotal (95% CI) 795 793 100.0% 1.41 [1.15, 1.72]
Total events: 184 (Risperidone), 130 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 4 (P = 0.98);I2 = 0.0%
Test for overall effect: Z = 3.33 (P = 0.00087)
0.1 0.2 0.5 1.0 2.0 5.0 10.0
Favours Risperidone Favours Control
Figure 22. Risperidone versus olanzapine, in relation to sleep problems/insomnia.
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Review: Risperidone versus olanzapine for schizophrenia
Comparison: 1 RISPERIDONE versus OLANZAPINE
Outcome: 25 Adverse events: 8b i. Metabolic parameters - weight - binary measures
Study or subgroup Risperidone
n/N
Olanzapine
n/N
Risk Ratio
M-H, Random, 95% CI
Weight Risk Ratio
M-H, Random, 95% CI
1 any gain
Casey et al.106 5/60 9/65 15.7% 0.60 [0.21, 1.69]
Keefe et al.104 17/158 22/159 43.9% 0.78 [0.43, 1.41]
Tran et al.102 (HGBG) 13/167 28/172 40.4% 0.48 [0.26, 0.89]
Subtotal (95% CI) 385 396 100.0% 0.61 [0.41, 0.91]
Total events: 35 (Risperidone), 59 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 = 0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
2 gain of more than 7% from baseline - short term
CATIE103 43/300 92/307 62.9% 0.47 [0.34, 0.65]
Conley and Mahmoud100 22/188 47/189 37.1% 0.47 [0.30, 0.75]
Subtotal (95% CI) 488 496 100.0% 0.47 [0.36, 0.61]
Total events: 64 (Risperidone), 139 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 = 0.0%
Test for overall effect: Z = 5.54 (P = 0.00001)
3 gain of more than 20% from baseline
Conley and Mahmoud100 0/188 4/189 100.0% 0.11 [0.01, 2.06]
Subtotal (95% CI) 188 189 100.0% 0.11 [0.01, 2.06]
Total events: 0 (Risperidone), 4 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
4 gain of more than 7% from baseline - to last observation longterm 
CATIE103 42/300 92/307 100.0% 0.47 [0.34, 0.65]
Subtotal (95% CI) 300 307 100.0% 0.47 [0.34, 0.65]
Total events: 42 (Risperidone), 92 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 4.54 (P = 0.00001)
5 weight gain and metabolic effects severe enough to cause withdrawl from 
this study
CATIE103 6/333 31/330 100.0% 0.19 [0.08, 0.45]
Subtotal (95% CI) 333 330 100.0% 0.19 [0.08, 0.45]
Total events: 6 (Risperidone), 31 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
0.1 0.2 0.5 1.0 2.0 5.0 10.0
Favours Risperidone Favours Olanzapine
Figure 23. Risperidone versus olanzapine, in relation to metabolic parameters/weight.
patients who responded to treatment (mean maximum dose: 12.9 mg 
of olanzapine and 3.14 mg of risperidone), while it did not change sig-
nificantly among the other patients (mean maximum dose: 14.5 mg of 
olanzapine and 5.50 mg of risperidone). Body weight, prolactin and to-
tal cholesterol increased significantly. 
The present authors concluded that an antipsychotic polypharmacy 
scheme might be useful for refractory patients, but the increase in ad-
verse events would need to be considered. New studies to evaluate com-
bination therapy consisting of antipsychotics versus clozapine or tena-
cious long-term monotherapy strategies would be needed to assess the 
response to refractory schizophrenia. 
Freudenreich et al.110 conducted a randomized parallel clinical dou-
ble-blind trial evaluating the effectiveness of risperidone in combina-
tion with clozapine for treating refractory schizophrenia. Twenty-four 
patients received a fixed dose of risperidone 4 mg/day for six weeks. The 
patients who received risperidone did not show any significant decrease 
in total PANSS scores. The PANSS subscale evaluation improved signif-
icantly (P = 0.047). The authors concluded that, according to the results 
obtained from this study, there were no additional benefits from the as-
sociation of risperidone and clozapine among patients with refractory 
schizophrenia. However, further trials would be needed in order make a 
definitive assessment regarding the efficacy of this combination. 
Lewis et al.111 conducted a randomized multicenter study in the Unit-
ed Kingdom in partnership with the National Health Service (NHS). 
The study included 136 participants aged 18-65 years diagnosed with 
schizophrenia	according	to	the	DSM-IV	whose	medication	was	changed	
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Review: Depot risperidone for schizophrenia
Comparison: 1 RISPERIDONE DEPOT (25, 50 or 75mg/2weeks) versus PLACEBO
Outcome: 1 Mental state: Exacerbation of specific symptoms
Study or subgroup Treatment  
n/N
Control  
n/N
Risk Ratio 
M-H, Fixed , 95% CI
Weight Risk Ratio 
M-H,Fixed, 95% CI
1 anxiety
Kane et al.108 27/302 15/98 100.0% 0.58 [0.32, 1.05]
Subtotal (95% CI) 302 98 100.0% 0.58 [0.32, 1.05]
Total events: 27 (Treatment), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
2 agitation
Kane et al.108 46/302 25/98 100.0% 0.60 [0.39, 0.92]
Subtotal (95% CI) 302 98 100.0% 0.60 [0.39, 0.92]
Total events: 46 (Treatment), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
3 hallucinations
Kane et al.108 19/302 5/98 100.0% 1.23 [0.47, 3.22]
Subtotal (95% CI) 302 98 100.0% 1.23 [0.47, 3.22]
Total events: 19 (Treatment), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
4 nervousness
Kane et al.108 6/302 5/98 100.0% 0.39 [0.12, 1.25]
Subtotal (95% CI) 302 98 100.0% 0.39 [0.12, 1.25]
Total events: 6 (Treatment), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
5 psychosis
Kane et al.108 37/302 23/98 100.0% 0.52 [0.33, 0.83]
Subtotal (95% CI) 302 98 100.0% 0.52 [0.33, 0.83]
Total events: 37 (Treatment), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0065)
0.1 0.2 0.5 1.0 2.0 5.0 10.0
Favours treatment Favours control
Figure 24. Injectable risperidone versus placebo, in relation to mental state/exacerbation of specific symptoms.
because of lack of clinical response from the use of two or more antipsy-
chotics. The participants were randomly assigned risperidone, clozapine, 
olanzapine, quetiapine or amisulpride. The results were evaluated by as-
sessors who were blinded to the allocation group. A one-year follow-up 
was conducted on 87% of the sample. Intention-to-treat analysis showed 
that there was no statistically significant difference in the scores on the 
quality-of-life scale regarding treatment with clozapine (3.63 points; CI: 
0.46 to 7.71; P = 0.08), but that there was a statistically significant ad-
vantage according to the total PANSS score (-4.93 points; CI -8.82 to 
-1.05; P = 0.013) at the one-year follow-up. Users of clozapine report-
ed a lower rate of extrapyramidal side effects. In the 12th week, the par-
ticipants who received clozapine reported that their mental health was 
significantly better, compared with participants receiving other antipsy-
chotics. The authors concluded that for patients with schizophrenia who 
did not respond to two or more antipsychotic medications, there was an 
advantage in treating with clozapine, in terms of improvement of symp-
toms over a one-year period.
Honer et al.112 conducted a randomized clinical double-blind trial 
to evaluate patients with schizophrenia who did not respond to treat-
ment with clozapine. Patients continued to take clozapine and were ran-
domly assigned to receive 3 mg of risperidone daily for eight weeks or a 
placebo. This course of treatment was followed by an optional addition-
al 18 weeks with risperidone. The main outcome evaluated was the re-
duction in the total score attributed to the severity of positive and nega-
tive symptoms, as measured by PANSS. Secondary outcomes included 
cognitive functioning. Sixty-eight patients were randomly assigned to 
treatment. In the double-blind phase, the mean total score for the se-
verity of symptoms decreased over the eight-week evaluation for both 
groups (risperidone and placebo). There was no statistically significant 
difference regarding the symptomatic benefit from associations with ris-
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Review: Depot risperidone for schizophrenia
Comparison: 1 RISPERIDONE DEPOT (25, 50 or 75mg/2 weeks) vs PLACEBO
Outcome: 3 Leaving the study early: 2. Any reason (by doses)
Study or subgroup Treatment 
n/N
Control 
n/N
Risk Ratio 
M-H, Fixed, 95% CI
Weight Risk Ratio 
M-H, Fixed, 95% CI
1 all doses risperidone depot
Kane et al.108 156/302 68/98 100.0% 0.74 [0.63, 0.88]
Subtotal (95% CI) 302 98 100.0% 0.74 [0.63, 0.88]
Total events: 156 (Treatment), 68 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.38 (P = 0.00071)
2 25mg risperidone depot
Kane et al.108 51/99 68/98 100.0% 0.74 [0.59, 0.94]
Subtotal (95% CI) 99 98 100.0% 0.74 [0.59, 0.94]
Total events: 51 (Treatment), 68 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
3 50mg risperidone depot
Kane et al.108 53/103 68/98 100.0% 0.74 [0.59, 0.93]
Subtotal (95% CI) 103 98 100.0% 0.74 [0.59, 0.93]
Total events: 53 (Treatment), 68 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.011)
4 75mg risperidone depot
Kane et al.108 52/100 68/98 100.0% 0.75 [0.60, 0.94]
Subtotal (95% CI) 100 98 100.0% 0.75 [0.60, 0.94]
Total events: 52 (Treatment), 68 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
0.1 0.2 0.5 1.0 2.0 5.0 10.0
Favours treatment Favours control
Figure 25. Injectable risperidone versus placebo, in relation to dropout from the study reported for any reason.
peridone and placebo: nine out of the 34 patients who received placebo 
and six out of the 34 who received risperidone responded to treatment 
(P = 0.38). The mean difference in PANSS score change from baseline 
to the eighth week, between those receiving risperidone and those re-
ceiving placebo was 0.1 (95% CI -7.3 to 7.0). The verbal working mem-
ory index showed a slight decline in the risperidone group and a small 
improvement in the placebo group (P = 0.02), comparing the changes 
in the two groups from baseline. The increase in blood glucose levels was 
higher in the risperidone group than in the placebo group. There was 
no difference between the groups regarding occurrence and severity of 
other side effects. The authors of the study concluded that there were no 
additional benefits from associating risperidone and clozapine among 
patients with severe schizophrenia.
DISCUSSION
This systematic review presents a broad overview of randomized 
controlled trials and systematic Cochrane reviews that have been con-
ducted in relation to the use of aripiprazole, paliperidone, quetiapine 
and risperidone for treating schizophrenia. There have been few studies 
in	the	literature	on	treatments	for	refractory	patients.	Only	a	single	Co-
chrane review examined nine studies comparing risperidone with clo-
zapine for treating refractory patients.14 The present paper has now up-
dated that review, with the addition of 10 RCTs as follows: two RCTs 
(aripiprazole), two RCTs (paliperidone), two RCTs (quetiapine) and 
four RCTs (risperidone). Among the drugs evaluated, risperidone has 
been on the market longer than other antipsychotics and has the best 
data for demonstrating its effectiveness in this subgroup of patients.
In comparing these four atypical antipsychotics with first-genera-
tion or typical antipsychotics, the main advantage of atypical antipsy-
chotics, which is common to all drugs in this category, is their favorable 
safety profile with regard to adverse extrapyramidal events. Side effects 
such as akathisia, parkinsonism and tardive dyskinesia often limit the 
long-term use of typical antipsychotics, thus leading to abandonment 
of	treatment	and	a	high	relapse	rate.	On	the	other	hand,	it	is	important	
to emphasize that the clinical trials included in this review, which were 
mostly short and medium-term studies, have not demonstrated clear 
advantages in treatment compliance. 
Regarding comparisons between atypical antipsychotics, the data 
are even more limited. The main drugs compared in clinical trials, some 
of which are specific to refractory schizophrenia, included amisulpride, 
clozapine, risperidone and olanzapine, because these are the drugs that 
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demonstrate improved efficacy profiles, compared with typical antip-
sychotics, thereby demonstrating advantages in terms of improving 
negative symptoms, for example.113 Likewise, users of risperidone and 
paliperidone have a greater propensity towards extrapyramidal events, 
which are potentially dose-dependent reactions. 
A systematic review by Leucht et al.113 evaluated comparisons be-
tween atypical antipsychotics alone that were identified in 78 RCTs 
with 13,558 participants. Its main conclusions were that: risperidone is 
more effective than quetiapine; ziprasidone olanzapine is more effective 
than aripiprazole, quetiapine, risperidone and ziprasidone (separately); 
and clozapine, at doses above 400 mg/day, is more effective than risperi-
done. These authors also concluded that, despite some differences in 
negative symptoms, the benefits (from atypical antipsychotics) basically 
relate to efficacy in dealing with positive symptoms of schizophrenia. 
One	important	matter	that	has	been	extensively	investigated	in	the	lit-
erature on the role of antipsychotics is long-term compliance. 
A study conducted in Brazil by Rosa et al.114 showed that after one 
year,	 50%	of	patients	 discontinued	 the	 treatment.	Over	 recent	 years,	
some studies in other countries, have taken the view that adherence to 
treatment should be the main endpoint for measuring the effectiveness 
of treatment, because this includes an assessment of the balance between 
the benefits (effectiveness) and risks to safety of these interventions.
The CATIE study (Clinical Antipsychotic Trials of Intervention 
Effectiveness),103 conducted by the NIMH (National Institute of Men-
tal Health, United States), included 1,460 individuals with schizophre-
nia in 57 centers in the United States, and patients with a first episode 
or refractory episodes were excluded. The percentages of patients who 
had discontinued treatment by the 18th month were: 64% on olanzap-
ine (mean dose 20.1 mg/day, n = 336); 74% on perphenazine (20.8 mg, 
n = 245); 75% on quetiapine (543.4 mg, n = 309); 79% on risperidone 
(3.9 mg, n = 305); and 82% ziprasidone (112.8 mg, n = 165). Patients 
taking olanzapine adhered better to treatment than did those taking 
quetiapine (P < 0.001) and risperidone (P = 0.002). 
The EUFEST study (European First Episode Schizophrenia Trial)115 
was a pragmatic multicenter study in 13 European countries and Israel, 
which evaluated 498 patients with newly diagnosed schizophrenia (less 
than two years) and was sponsored by AstraZeneca, Pfizer and Sanofi-
Aventis. The rate of discontinuation of treatment after one year was 
22% with amisulpride (200-800 mg, n = 104); 34% with haloperidol 
(1-4 mg, n = 103); 22% with olanzapine (5-20 mg, n = 105); 33% with 
quetiapine (200-750 mg, n = 104); and 36% with ziprasidone (40-160 
mg,	n	=	82).	Dropouts	among	patients	on	haloperidol	occurred	earlier	
than with other drugs (P < 0.01). 
In addition to the choice of depot antipsychotic medications, quar-
terly or monthly use can also be a significant factor in improving adher-
ence to treatment among individuals with schizophrenia. Antipsychot-
ics with prolonged action, such as haloperidol decanoate, pipotiazine, 
zuclopenthixol and penfluridol, have been important therapeutic op-
tions since the 1960s. They act by keeping the plasma levels of the active 
agent stable, thereby improving adherence and preventing relapses. In 
fact, relapse prevention is one of the main targets in treating schizophre-
nia and is therefore considered to be one of the most important out-
come criteria used to assess the effectiveness of an antipsychotic drug. 
However, it is well established that chronic use of first-generation antip-
sychotics may be associated with the development of extrapyramidal ef-
fects, (e.g. tardive dyskinesia), and in this sense, conventional depot an-
tipsychotics may not be the best treatment option, despite their proven 
efficacy.	On	the	other	hand,	it	has	already	been	shown	that	long-term	
use of second-generation antipsychotics is associated with a lower risk of 
developing extrapyramidal symptoms. Thus, use of second-generation 
depot antipsychotics, such as risperidone, for patients who adhere to 
treatment, represents a substantial improvement in combating the de-
velopment of schizophrenia.
Combinations of antipsychotics for refractory cases of schizophre-
nia have also been used, and studies have shown some clinical bene-
fits, but also a deterioration of tolerability. A systematic review pub-
lished in 2009116 evaluated association strategies, and demonstrated that 
the benefits occurred mainly in relation to associations between typical 
and atypical antipsychotics, and not in relation to associations between 
two typical antipsychotics or between two atypical antipsychotics. These 
data have not been confirmed, but may be relevant to clinical practice 
(Table 1).116
Finally, clozapine remains the only drug specifically indicated for 
treating refractory schizophrenia according to the British NHS. There-
fore, clinicians should consider this to be an option for patients present-
ing resistance to treatment. Certain serious medical conditions relating 
to schizophrenia are particularly sensitive to clozapine, including persis-
tent auditory hallucinations, persistent hostility, suicide risk and tardive 
dyskinesia. The main limitation on the use of clozapine is the need for 
monitoring and prevention of agranulocytosis, which affects 1% of pa-
tients for which patients need to have blood samples drawn regularly. 
CONCLUSIONS
In treating schizophrenia, the antipsychotics quetiapine, aripipra-
zole and paliperidone were not associated with statistically significant 
differences in outcome improvement regarding overall psychopathol-
ogy, as measured using scales such as PANSS, BPRS or CGI, in com-
parison with first-generation antipsychotics. Risperidone was specifi-
cally evaluated among patients with refractory schizophrenia in one of 
Table 1. Efficacy of associations between antipsychotics1116
Antipsychotics Patients
RR 
(95% CI)
NNT 
(95% CI)
P value
Typical versus atypical 438 ns – 0.37
Atypical + atypical versus typical 336 ns – 0.65
Atypical + typical versus typical 171 0.47 (0.22-0.98) 3 (2-9) 0.004
Atypical + typical versus atypical 257 0.59 (0.40-0.88) 3 (2-6) < 0.0001
RR = relative risk of antipsychotics; 95% CI = 95% confidence interval; NNT = number needed to treat; ns = non-significant.
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the systematic reviews included here, and this demonstrated favorable 
but not definitive outcomes, compared with drugs that have also been 
shown to be effective, such as amisulpride, clozapine and olanzapine. 
A lower frequency of extrapyramidal side effects has been reported in 
RCTs that evaluated quetiapine, aripiprazole, paliperidone and risperi-
done in comparison with first-generation antipsychotics. 
Implications for clinical practice 
Although there are several antipsychotics on the market and new 
drugs are released regularly, the population of patients with refractory 
schizophrenia still remains high. These people present limited response 
to antipsychotics and persist with residual psychotic symptoms. Treat-
ment with first and second-generation antipsychotics may have similar 
efficacy; however, patients treated with atypical antipsychotics are more 
likely to adhere to treatment. Investigation of dose adequacy and even 
the particular combinations of antipsychotics are also among the actions 
that can provide benefits for some patients.
Implications for research
There remains a need for studies to evaluate the effectiveness of in-
terventions	for	patients	with	refractory	schizophrenia.	Outcomes	of	risk	
profile, long-term benefit, relapse rates, residual symptoms, safety and 
cost-effectiveness of antipsychotics need to be better established. Among 
the outcomes to be studied, treatment compliance is an indicator that 
assesses the balance between efficacy and safety. It is a good means of as-
sessing the overall effectiveness of an antipsychotic drug and should be 
considered a primary outcome. Quality of life, wellbeing and all assess-
ments of personal and family interventions also need to be better evalu-
ated. Studies on depot antipsychotics, and particularly atypical antipsy-
chotics, are very relevant for such patients. Finally, studies on associa-
tions between antipsychotics are very relevant in this situation of such 
limited information on clinical outcomes. 
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